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ABSTRACT: 3-Deoxy-β-D-manno-oct-2-ulosonic acid (β-Kdo) glycosides are mainly found in 
capsular polysaccharides (CPS) and extracellular exopolysaccharides (EPS) from Gram-negative 
bacteria. These compounds have profound biological implications in immune response and act as 
virulence factors. We have developed a novel methodology for the stereoselective synthesis of β-
Kdo glycosides via the use of a 4′-methoxyphenacyl (Phen) auxiliary group at the C1 position of 
a peracetylated β-Kdo thioglycoside. Under the promotion of NIS/AgOTf in acetonitrile, a series 
of Kdo glycosides was synthesized in good yield and β-selectivity while minimizing the 
formation of undesirable glycals. Stereoselectivity of the glycosylation was shown to be 
modulated by various factors such as promotor, solvent, anomeric ratio of donor, nature of 
acceptor, and Phen substitution. Chemoselective cleavage of the Phen group was performed 
under the action of Zn/HOAc. DFT calculations together with experimental results suggested that 
α-triflate and a six-membered α-spiroPhen are plausible intermediates of the reaction, accounting 
for the enhanced formation of β-Kdo glycosides. The developed methodology could be applied to 
the synthesis of β-Kdo-containing glycans from pathogenic bacteria. 
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3-Deoxy-D-manno-oct-2-ulosonic acid (Kdo) glycosides are mainly found in the surface 
polysaccharides of bacteria.1 Kdo glycosides with the α-configuration are present in virtually all 
of the lipopolysaccharide (LPS) core regions of Gram-negative bacteria, playing a crucial role in 
the structural integrity of bacterial membranes.2 In contrast, β-Kdo glycosides occur far less 
frequently within LPS. Rare occurrences include: 1) LPS core regions from Alteromonas 
macleodii;3 2) LPS O-antigen (OAg) from Providencia alcalifaciens;4 and 3) non-reducing end of 
LPS OAg from Klebsiella pneumoniae serotype O12.5 The most frequent occurrence of β-Kdo 
glycosides is within the repeating unit of capsular polysaccharides (CPS),1 which are known as 
virulence factors and are involved in protection from host immune mechanisms.6 For instance, 
Kingella kingae, a Gram-negative bacteria causing septic arthritis, osteomyelitis, and bacteremia 
in young children, produces a CPS featuring a repeating disaccharide comprised of a Kdo residue 
in the β-configuration (Figure 1).7 β-Kdo glycosides have also been found in extracellular 
exopolysaccharides (EPS), such as the one expressed by the ʻTier 1 Select Agentʼ Burkholderia 
pseudomallei, the causative agent of melioidosis.8-10 Cytidine monophosphate (CMP)-Kdo,11,12 
the activated sugar nucleotide processed by Kdo glycosyltransferases, is another important 
example of a naturally occurring compound bearing a β-Kdo unit. Recently, Whitfield and co-
workers13 have highlighted the presence of poly-Kdo linkers, containing alternating β-(2→4) and 
β-(2→7) linkages, at the reducing end of CPS from various Gram-negative pathogens including 
Escherichia coli, Campylobacter jejuni, Haemophilus influenza, Neisseria meningitides, and 
Pasteurella multocida. Enzymes involved in the biosynthesis of these poly-Kdo linkers have been 
characterized as novel retaining Kdo transferases (KpsC and KpsS).14,15 Owing to the structural 
significance and biological importance of β-Kdo residues in bacterial polysaccharides, 
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straightforward synthetic routes towards β-Kdo glycosides are needed.16,17 Access to these 
compounds in pure and homogeneous forms would further the development of vaccines, 
diagnostics and therapeutics against some clinically relevant bacterial pathogens.1,2,18 
 
 
Figure 1. Naturally occurring β-Kdo-containing glycans from bacteria. 
 
The synthesis of Kdo glycosides is not a trivial task, and shares similarities with the glycosylation 
of N-acetylneuraminic acid (Neu5Ac).19 The lack of a hydroxyl group at the C3 position, which 
hampers the use of the neighboring group participation effect, the presence of an electron 
withdrawing carboxylic acid at C1, which deactivates and hinders the anomeric position, and the 
undesirable formation of 2,3-glycals are the main issues regarding the synthesis of Kdo 
glycosides.16,17 In the last few years, novel methodologies have been implemented allowing 
access to α-Kdo glycosides in excellent yields and stereoselectivity. In this respect, it is worth 
mentioning the use of 5,7-O-di-tert-butylsilylene protected thioglycoside20 and 3-iodo fluoride21-
23 donors. Yet, the synthetic chemistry of Kdo glycosides having the opposite thermodynamically 
less stable β-configuration (OR group in equatorial rather than axial position) still requires 
improvements.16 
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Towards this aim, Ling and co-workers,24 relying on the pioneering work of Takahashi,25 
developed a novel class of 4,5;7,8-di-O-isopropylidene protected 1-C-arylglycal donors, which, 
upon treatment with N-iodosuccinimide (NIS), led to the stereoselective formation of β-Kdo 
glycosides. Yet, their approach required a supplemental reductive deiodination step followed by 
an oxidative transformation in order to provide the carboxylic acid at C1. Recently, Mong and co-
workers26 partially resolved the latter issue by preparing Kdo glycal donors bearing a preinstalled 
carboxylate at C1. NIS-mediated glycosylation of these glycals in a DCM/CH3CN mixture led to 
β-Kdo glycosides in a β/α ratio of up to 20:1 following radical deiodination. In both previous 
cases, the presence of a 4,5-O-isopropylidene group locking the pyranose ring into a skew-boat 
conformation was found to be essential for providing high β-stereoselectivity. Using unlocked 
perbenzylated or peracetylated Kdo glycals led to the opposite trans-diaxial selectivity with 
regard to the C3 iodine atom and C2 OR group.25,27 
 
There have been few reports regarding the synthesis of β-Kdo glycosides with ‘non-glycal’ 
donors. van Boom and co-workers28,29 were the first to show that reacting peracetylated β-Kdo 
thioglycosides with NIS/TfOH could provide Kdo glycosides in the major β-configuration when 
3-amino-N-benzyloxycarbonyl-1-propanol was used as an acceptor. More recently, an interesting 
study by the group of Oscarson27 revealed that peracylated β-Kdo thioglycosides were suitable 
donors for the formation of β-Kdo glycosides bearing 2-(4-trifluoroacetamidophenyl)ethyl as a 
spacer when DMTST or IBr/AgOTf were used as promoters. In all these studies, however, no 
systematic evaluations of the glycosylation conditions were performed and no mechanistic details 
were provided. Herein, we report a novel approach for the stereoselective synthesis of β-Kdo 
glycosides involving the use of a long-range participating 4′-methoxyphenacyl (Phen) auxiliary 
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group at the C1 position. Glycosylation conditions were thoroughly investigated both in the 
presence and in the absence of the Phen group, e.g. promoters, leaving groups, anomeric 
configuration of donors, solvents, nature of acceptors, addition order of reagents, and counter-
anions. On the basis of DFT calculations and experimental details, we also propose plausible 
intermediates accounting for the formation of both α- and β-Kdo glycosides under the optimized 
reaction conditions. 
 
RESULTS AND DISCUSSION 
 
Synthetic Approach. Long-range participating effects through the use of an auxiliary group have 
been previously described for the synthesis of α-Neu5Ac glycosides, which display structural 
similarities with β-Kdo glycosides. The presence of ester chains at the C1 position of Neu5Ac, 
such as 2-methylthioethyl, 2-phenylthioethyl,30 and N,N-dimethylglycolamide,31,32 was shown to 
enhance the α-selectivity of the glycosylation reaction via the stabilization of the oxocarbenium 
ion from the β-axial orientation, thereby favoring the attack of the nucleophile from the α-face. 
Enhanced α-selectivities were also observed for Neu5Ac thioesters33 and 2-cyanoethyl esters34 in 
conjunction with CH3CN, presumably through a mechanism involving stabilization of the β-
oriented nitrilium ion. 
 
Inspired by these previous studies, we have devised an analogous approach to tackle the problem 
of β-Kdo glycosides synthesis via the use of a 4′-methoxyphenacyl (Phen) auxiliary group at the 
C1 position of peracetylated Kdo donors. Our choice was driven by two important factors: 1) the 
enhanced electronic density of the ketone functionality that would be likely to participate 
favorably in the course of the glycosylation reaction, and 2) the orthogonality of phenacyl 
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groups35 with several base- and acid-sensitive protecting groups that would be an asset over 
previously reported auxiliary groups. 
 
Our working hypothesis is depicted in Figure 2. Once the Kdo donor is activated by a suitable 
electrophilic promoter, the oxocarbenium ion (glycosyl cation)36 will be formed. According to 
Woerpel,37-40 the attack of the electron-rich ketone from the α-face of the 5H4 half-chair 
conformer would be favored in order to minimize the destabilizing 1,3-diaxial interactions. The 
resulting six-membered α-spiro compound, which could be found either as a covalent or contact 
ion pair intermediate, would then be attacked by the acceptor preferentially from the opposite β-
face leading to enhanced β-selectivity for the formation of Kdo glycosides. DFT calculations at 
the B3LYP/6-311++G(2d,2p) level of theory tend to support this hypothesis since the α-spiro 
intermediate was found to be energetically favored compared to the β-spiro intermediate by 13.0 
kJ⋅mol−1 (see Figure S1 and Table S1). Moreover, these two intermediates were at least 36.8 
kJ⋅mol−1 more stable than the free oxocarbenium ion. Nevertheless, it is important to point out 
that, in the case of a Curtin-Hammett scenario in which there is a rapid exchange between both 
intermediates, the major product could also arise from the higher energy ground state 
intermediate.41,42 Furthermore, it has to be stressed out that a conformational change from the 
more stable Z-ester to the less stable E-ester must occur in order to allow the phenacyl ketone to 
approach the glycosyl cation. According to the literature, the energy difference for the Z/E ester 
isomerization is about 12.5 kJ⋅mol−1.43 This energy barrier can be lowered by using polar 
solvents, such as acetonitrile, or when an electron-withdrawing group is attached to the R′ 
position of a RCO2R′ ester, such as a phenacyl group.
44 In the case of our work, the Z/E ester 
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isomerization would be beneficial in terms of energy because it opens the way for the formation 




















































































Figure 2. Proposed approach for the synthesis of β-Kdo glycosides through the use of a 4′-
methoxyphenacyl (Phen) C1-auxiliary group. A = activating group; E = electrophile. The 3D 
structures were obtained by DFT geometrical optimization at the B3LYP/6-311++G(2d,2p) level 
of theory (hydrogen atoms have been omitted for the sake of clarity). 
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Synthesis of Kdo Donors. The synthesis of peracetylated Kdo thioglycoside and fluoride donors 
2-5 bearing participating (Phen) or non-participating (Bn) ester groups was investigated first 
(Scheme 1). Crystalline ammonium Kdo was obtained through the modified Cornforth 
procedure45-47 using an optimized methodology recently reported by Kosma.48 This allowed us to 
prepare gram quantities of pure Kdo in a reliable manner. Ammonium Kdo was subjected to 
acetylation under standard conditions (Ac2O, py, DMAP, rt) leading to peracetylated 1
49 with 
nearly quantitative yield. Performing the reaction at more elevated temperatures (>30 °C) 
generated substantial amounts of Kdo lactone.50 Then, two different routes were studied for the 
synthesis of thioglycosides 2 and 3. Esterification with 4′-methoxyphenacyl bromide (PhenBr) or 
BnBr in the presence of Cs2CO3 followed by glycosylation with EtSH under the action of 
BF3⋅OEt2 produced donors 2 and 3 with 15 and 67% yield, respectively, both predominantly 
featuring the β-configuration as expected27 (β/α 9:1 for 2, and 7:1 for 3). The low yield obtained 
for the Phen derivative 2 was due to the formation of an undesirable by-product, presumably a 
dithioketal coming from the addition of two EtSH molecules on the activated ketone (LRMS: m/z 
[M + Na] calcd for C31H44O12S3 727.2; found 727.7). Another route was then investigated in 
which free acid 1 was first refluxed in DCE with EtSH and BF3⋅OEt2 followed by esterification of 
the resulting thioglycoside. Using this route, donors 2 and 3 were obtained in convenient yields 
(45 and 50%, respectively), but with different anomeric ratios than route A (β/α ∼1:1). Fluoride 
donors 4 and 5 were synthesized via a similar approach. Regioselective fluorination at the 
anomeric position was performed by treatment of peracetylated 1 with HF⋅py 7:3 followed by 
standard esterification to provide donors 4 and 5 with 49 and 45% yield, respectively.51 The 
exclusive α-configuration of these fluoride donors was confirmed by 19F NMR analysis (3JF,H3ax = 
34.6 Hz, 3JF,H3eq = 6.0 Hz). 
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Scheme 1. Synthesis of Kdo Thioglycoside and Fluoride Donors 
 
 
In order to provide donor 2 with the same anomeric ratio as 3 (β/α 7:1, route A) and to improve 
the yield, an additional methodology was investigated for comparison purposes (Scheme 2). 
Therefore, hydrogenolysis of thioglycoside 3 followed by esterification under the above-
mentioned conditions provided donor 2 with a good yield (76%) without erosion of 
diastereoselectivity (β/α 7:1). Furthermore, this approach allowed us to synthesize Kdo 
thioglycoside donors bearing 3′-methoxy (6), 2′-methoxy (7) as well as unsubstituted (8) 
phenacyl groups all having the same β/α ratio (7:1). 
 
Scheme 2. Synthesis of β-Kdo Thioglycoside Bearing Diversely Substituted Phenacyl 
Groups 
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Synthesis of β-Kdo Glycosides. With Kdo donors (2-8) in hand, study of their glycosylation 
behavior for the selective formation of β-Kdo glycosides was investigated next. Using Phen 
thioglycoside 2 in a ∼1:1 β/α ratio together with 5-amino-N-benzyloxycarbonyl-1-pentanol (9,52 
Figure 3) as a model acceptor, we first screened different thiophilic promoters (Table 1). 
Glycosylation reactions in entries 1 to 8 were conducted in the non-participating solvent DCE at 
–10 °C in the presence of water scavenging 4 Å molecular sieves, and the β/α selectivity ratio 
was evaluated by 1H NMR analysis. At this temperature, all promoters were shown to give 




Figure 3. Glycosyl acceptors (9-14) used in this study. 
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Table 1. Synthesis of β-Kdo Glycosides: Promoter and Solvent Screening 
 






15β 15α 16 
1 IBr/AgOTf DCE >95 1.5 1.0 nd
b 
2 MeOTf DCE 60 2.4 1.0 0.8 
3 Me2S2/MeOTf
c 
DCE >95 3.7 1.0 2.0 
4 Me2S2/Tf2O DCE >95 3.0 1.0 1.0 
5 NCS/TfOH DCE >95 5.0 1.0 5.7 





41 6.0 1.0 nd 
8 NIS/AgOTf DCE >95 4.7 1.0 0.6 
9 NIS/AgOTf Et2O >95 5.8 1.0 nd 
10 NIS/AgOTf CH3CN >95 (84)
e 
7.9 1.0 nd 
11 NIS/AgOTf
f
 CH3CN >95 nd nd 1.0 
12 NIS/AgOTf
f
 DCE >95 nd nd 1.0 
13 NIS/AgClO4 CH3CN >95 3.2 1.0 nd 
14 NIS/AgBF4 CH3CN >95 3.2 1.0 nd 
aDetermined by 1H NMR analysis of the crude reaction mixture. bNot detected. cIn situ formed  
DMTST. dPerformed at –40 °C. ePerformed at 1.25 mmol scale. Value in parentheses 
corresponds to the isolated yield of 15β and 15α. fDonor and reagents were premixed before the 
addition of acceptor 9 (preactivation conditions). 
 
In contrast with the results of Oscarson,27 the use of IBr/AgOTf53 gave the lowest β/α ratio 
(1.5:1.0) without formation of glycal 16 (entry 1). We interpreted this result as a competitive 
attack of the nucleophilic bromide anion at the anomeric center, forming a reactive β-bromide 
species54 that can be displaced from the α-face by the acceptor. Using Me2S2/MeOTf (DMTST)
55 
or Me2S2/Tf2O
56 provided better β-selectivity (up to 3.7:1.0) but glycal formation was observed 
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(entries 3 and 4). Enhanced formation of Kdo glycoside 15β was found with N-chlorosuccinimide 
(NCS)/TfOH as the promoter (β/α 5.0:1.0) but, again, substantial amounts of glycal 16 were 
formed (entry 5). Switching to NIS57-59 significantly decreased the formation of 16 but kept good 
β-selectivity (entry 6). Conducting the reaction at –40 °C with NIS/TfOH prevented glycal 
formation (entry 7); however, conversion of the donor was not complete (∼41%). 
 
We next examined the use of NIS/AgOTf59 as the promoter, which gave the best results in terms 
of β-selectivity while minimizing glycal formation (entry 8). This result was somewhat 
unexpected since Oscarson27 showed that a similar peracetylated methyl ester Kdo thioglycoside 
only furnished elimination product following treatment by NIS/AgOTf in DCM. We then 
explored the use of well-known participating solvents such as Et2O and CH3CN (entries 9 and 
10).60 The outcome of these reactions was found to be promising: complete conversion of donor 
2, enhanced β-selectivity, and no formation of glycal were observed. The reaction in CH3CN was 
performed at 1.25 mmol scale providing Kdo glycoside 15 in 84% yield with a β/α ratio of 
7.9:1.0. We hypothesized that preactivation conditions61 would be valuable in order to favor the 
formation of the α-spiro intermediate and would thereby potentially enhance the β-selectivity. 
Unfortunately, premixing donor 2 with NIS/AgOTf before adding acceptor 9 led exclusively to 
glycal 16, either in participating (CH3CN) or non-participating (DCE) solvents (entries 11 and 
12). The effect of counter-anions62,63 was also studied. Therefore, promoters containing anions 
less-coordinating than OTf– such as NIS/AgClO4 and NIS/AgBF4 were evaluated (entries 13 and 
14). Using these promoters, β-selectivity decreased by more than two-fold, implying that the 
reaction intermediates were sensitive to the strength of the coordinating anion. On the basis of 
this result, we can hypothesize that a covalently-bound (or contact-ion pair) triflate could be one 
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of the intermediates involved in the glycosylation reaction although this has not been 
experimentally proven. 
 
These results were then compared to those obtained with donor 3 (β/α ratio of ∼1:1) bearing a 
non-participating benzyl ester at C1 (Table 2). The advantage of using the Phen auxiliary group 
was clearly demonstrated here. Indeed, under the promotion of NIS/AgOTf, enhanced β-
selectivity was obtained with donor 2 compared to donor 3 (entries 1 to 4). Notably, the β/α ratio 
increased by more than two-fold when CH3CN was used as the solvent (7.9:1.0). Impact of the 
starting anomeric ratio of donors 2 and 3 was investigated next (entries 5 to 10). As shown in 
previous studies,28,29 performing the reaction with Kdo thioglycosides as major β-anomer 
(7.0:1.0) significantly improved β-selectivity (up to β/α 11.0:1.0 in CH3CN, entry 8). For all of 
these reactions, donor 2 bearing a Phen group provided better β-selectivity than benzyl ester 3 
and no glycal (16 or 18) was detected. As previously mentioned, the use of IBr instead of NIS 
decreased selectivity. Next, reactions were performed with α-fluoride donors 4 and 5 in order to 
probe the impact of the leaving group (entries 11 and 12). Six equiv. of BF3⋅OEt2 were needed to 
ensure full conversion of these fluorides.64 Similarly to thioglycosides, β-selectivity was 
enhanced when the Phen group-containing donor 4 was used in comparison with donor 5 
although the formation of glycals 16 and 18 was predominant. 
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β α glycal 
1 3 (1:1) DCE 90 3.8 1.0 nd
b 
2 2 (1:1) DCE >95 4.7 1.0 0.6 
3 3 (1:1) CH3CN 93 3.4 1.0 nd 
4 2 (1:1) CH3CN >95 7.9 1.0 nd 
5 3 (7:1) DCE >95 4.8 1.0 nd 
6 2 (7:1) DCE >95 10.8 1.0 nd 
7 3 (7:1) CH3CN >95 (94)
c 
6.3 1.0 nd 
8 2 (7:1) CH3CN >95 11.0 1.0 nd 
9 3 (7:1) CH3CN
d 
>95 3.0 1.0 nd 
10 2 (7:1) CH3CN
d 
>95 4.0 1.0 nd 
11 5 (0:1) DCM
e
 >95 1.0 4.0 1.1 
12 4 (0:1) DCM
e 
>95 1.0 1.0 1.4 
aDetermined by 1H NMR analysis of the crude reaction mixture. bNot detected. cPerformed at the 
gram scale. Value in parentheses corresponds to the isolated yield of 17β and 17α. dIBr was used 
instead of NIS. eFluoride donors 4 and 5 were activated with BF3⋅OEt2 (6.0 equiv) and the 
reaction performed at 0 °C for 2 h. 
 
The impact of phenacyl substitution on β-selectivity was also examined. As depicted in Scheme 
3, thioglycoside donors 6 and 7, bearing the methoxy group at positions 3′ and 2′ on the aromatic 
ring, respectively, as well as previously described 2 and unsubstituted 8 were coupled with 
acceptor 9 through the optimized glycosylation conditions, thereby generating Kdo glycosides 15, 
and 19-21 with yields ranging from 73 to 80%. Owing to the electron-donating properties of the 
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methoxy group, it was anticipated that 4′ and 2′-substituted Phen derivatives 2 and 7 would give 
the highest β/α ratios on an electronic effect basis. Although this was true for donor 2, only 
moderate β-selectivity (4.6:1.0) was obtained with donor 7. Moreover, similar β/α ratios were 
obtained for donors 6 and 8 (∼6.4:1.0), as expected. These results mean that both electronic and 
steric effects could be responsible for the formation of the plausible α-spiro intermediate, which 
accounts for the enhanced β-selectivity.  
 
Scheme 3. Impact of Phenacyl Substitution on β/α Ratio 
 
 
Having studied various parameters modulating β-selectivity, we next investigated the general 
scope of the glycosylation reaction. In order to do so, a series of acceptors (Figure 3) featuring 
primary, secondary, or tertiary alcohols, including 1-nonanol (10), cyclohexanol (11), 2-
adamantanol (12), 1-adamantanol (13), and methyl 2,3-di-O-benzyl-α-D-glucopyranoside (14) 
was reacted with thioglycoside donors 2 and 3 under the optimized conditions, i.e. NIS/AgOTf, 
CH3CN, –10 °C (Scheme 4). Using 1.4 equiv. of acceptors 10-14, the reactions provided Kdo 
glycosides 22-31 with fair to very good yields (40-87%) while minimizing the formation of 
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glycals 16 and 18. In all cases, β-Kdo glycosides were formed predominantly with the exception 
of the glycosylation of donor 3 with 1-adamantanol (13) that was moderately α-selective (β/α 
1.0:1.6). Once again, the effect of the Phen auxiliary group at C1 significantly enhanced β-
selectivity in all cases (up to two-fold) compared to the non-participating benzyl ester. It is worth 
mentioning that using Phen donor 2 with acceptor 13 led to an inversion in selectivity giving a 
slight excess of β-Kdo glycoside 28 (β/α 1.6:1.0). Moreover, glycosylation with 4,6-diol 14 was 
fully regioselective at the C6 primary position. 
 
Scheme 4. Scope of the Synthesis of β-Kdo Glycosides using Different Acceptors 
 
 
Determination of Anomeric Configuration of Kdo Glycosides. Since Kdo glycosides lack an 
anomeric proton at the C2 position, determination of anomeric configuration is not as 
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straightforward as it is for other glycosides and cannot rely only on 1H NMR analysis. One of the 
most accurate method is the determination of the coupling constant between carbonyl carbon at 
C1 and axial proton at C3.49 For Kdo glycosides adopting a 5C2 conformation, which is the case 
for glycosides 22-31, a 3JC1,H3ax value of 5.0-7.0 Hz is indicative of a β-configuration while a 
value ≤1.0 Hz denotes an α-configuration. Thus, the α- or β-anomeric configuration of Kdo 
glycosides 22-31 was determined via examination of this coupling constant obtained from an 
undecoupled 150 MHz 13C NMR experiment. As expected, 3JC1,H3ax values were found to be 
between 5.0-7.0 Hz for β-glycosides and ≤1.0 Hz for α-glycosides. Furthermore, an interesting 
empirical observation was made by comparing the 1H NMR data of α- and β-Kdo glycosides. We 
found that the two geminal protons at C8 were closer (or superimposed) for β-Kdo glycosides 
while the difference of the chemical shifts (∆δ) between H-8a and H-8b were more pronounced 
for α-Kdo glycosides (∆δ from 0.46 to 0.54 ppm). This statement was true for all of the 
synthesized Kdo glycosides. However, ∆δ values between H-3ax and H-3eq were not always 
smaller for α-glycosides, especially for 1- and 2-adamantyl glycosides 26-29, and thus, as 
recently emphasized by Mong,26 this empirical method could not be reliably used for determining 
the anomeric configuration of Kdo glycosides. 
 
Deprotection of Phenacyl Group. As previously mentioned, one of the main advantage of using 
a Phen auxiliary group lies in its possible chemoselective cleavage in the presence of other 
protecting groups. As examples, Kdo glycosides 22 and 15 were reacted with activated Zn 
powder in the presence of AcOH at 35 °C for 2 h (Scheme 5) to produce free carboxylic acids 32 
and 33 with very good yields (85 and 89%, respectively). The Phen derivatives were thus 
deprotected chemoselectively in the presence of acetyl and NHCbz groups showing the 
orthogonality of this auxiliary functionality. Importantly, other reaction conditions that have not 
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been tested in the course of this study could also be suitable for the selective cleavage of 
phenacyl groups including (Bu3Sn)2O in refluxing DCE; TBAF in THF; H2, Pd/C; and 
photodeprotection.65 
 
Scheme 5. Zn-Mediated Cleavage of Phenacyl Group 
 
 
Proposed Mechanism. On the basis of the above experimental results, DFT calculations, and 
literature precedent,66 reaction mechanism and plausible intermediates were proposed, accounting 
for the formation of both α- and β-Kdo glycosides. As shown in Figure 4, NIS would react with 
AgOTf to form an electrophilic species that would activate Kdo thioglycoside donors 2 or 3. 
Following activation, oxocarbenium ion I would be formed together with EtSI and a proton 
acceptor imine. DFT calculations showed that, owing to the highly unstable nature of 
intermediate I, it is likely that acetyl group at C4 would stabilize ion I from the β-face, thereby 
forming dioxalenium ion intermediate II in the B3,6 conformation (Figure S1). α-Triflate III 
would also be a plausible intermediate, which would be stabilized by the electron-withdrawing 
nature of acetyl groups and carboxylate at C1. Calculations revealed that triflate III would exist 
in the 5C2 conformation and be a stable intermediate. As previously discussed, α-spiroPhen IV 
would be a plausible intermediate, which would be formed by the attack of the Phen activated 
ketone on the α-face of oxocarbenium ion I. For Kdo donors bearing a Phen group, all these 
intermediates (I to IV) would exist in equilibrium reacting in different ways with the acceptor 
(R1OH). Glycosylation of oxocarbenium ion I, according to Woerpel model, as well as β-
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dioxalenium ion II would produce α-Kdo glycoside as the major anomer. On the other hand, 
glycosylation of α-triflate III and α-spiroPhen IV would occur from the β-face leading to the 
preferential formation of β-Kdo glycoside. α-Triflate III would thus represent a plausible 
intermediate, accounting for the good β-selectivity obtained with Kdo donor 3 bearing a non-
participating benzyl ester. Limitations of this mechanistic pathway include difficulties in 
explaining the impact of the starting anomeric ratio of donors giving enhanced β-selectivity for β-
Kdo thioglycosides in comparison with their α-counterparts (retention of configuration). 
Moreover, we cannot rule out the possibility that the generated N-succinimide (NHS) would trap 
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Figure 4. Proposed mechanism and plausible intermediates for the synthesis of β-Kdo 





In summary, a novel methodology was developed for the stereoselective formation of β-Kdo 
glycosides by taking advantage of the long-range participating effect of a 4′-methoxyphenacyl 
auxiliary group at the C1 position of a peracetylated Kdo thioglycoside donor. In addition to the 
positive effect of the Phen group, various parameters were shown to be crucial for enhancing the 
β-selectivity of the reaction, including NIS/AgOTf as promoter, CH3CN as solvent, β-anomeric 
configuration of the donor, as well as para-substitution of the Phen aromatic ring. The optimized 
glycosylation conditions were applied to the synthesis of a series of Kdo glycosides, providing 
good yields and β-selectivity while minimizing the formation of undesirable glycals. 
Interestingly, chemoselective deprotection of the Phen group was achieved using activated 
Zn/HOAc, which represents an advantage over previously reported C1 auxiliary groups. α-
Triflate and six-membered α-spiroPhen were postulated as plausible intermediates, accounting 
for the enhanced β-stereoselectivity obtained with Kdo thioglycoside donors bearing non-
participating (Bn) or participating (Phen) groups at C1. The developed methodology could find 
application for the synthesis of β-Kdo-containing oligosaccharides from pathogenic bacteria. 
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General Methods. All starting materials and reagents were purchased from commercial sources, 
and used as received without further purification. Air and water sensitive reactions were 
performed in heat gun-dried glassware under Ar atmosphere. Moisture sensitive reagents were 
introduced via a dry syringe. Anhydrous solvents were supplied over molecular sieves, and used 
as received. Petroleum ether (PE) refers to the 40-60 °C boiling fraction. Powdered 4 Å 
molecular sieves (MS) were activated before use by heating with a heat gun for ≥5 min under 
high vacuum. Reactions were monitored by thin-layer chromatography (TLC) with silica gel 60 
F254 0.25 mm pre-coated aluminium foil plates. Compounds were visualized by using UV254 
and/or orcinol (1 mg⋅mL−1) in a 10% H2SO4(aq) solution and/or Hanessian’s stain [2.5 g 
(NH4)6Mo7O24⋅4H2O, 1.0 g Ce(NH4)4(SO4)4⋅2H2O, 90 mL H2O, 10 mL H2SO4] with heating. 
Normal-phase flash column chromatography was performed on silica gel 60 Å (15-40 µm). NMR 
spectra were recorded at 297 K in the indicated solvent (CDCl3 or MeOD) with 400 or 600 MHz 
instruments, employing standard software provided by the manufacturer. 1H and 13C NMR 
spectra were referenced to tetramethylsilane (TMS, δH = δC = 0.00 ppm) as internal reference for 
spectra in CDCl3 and MeOD. Assignments were based on 
1H, 13C, undecoupled 13C, DEPT-135, 
COSY, HSQC, and HMBC experiments. High-resolution mass spectra (HRMS) were recorded 
on an ESI-Q-TOF mass spectrometer. 
 
Computational Method. Reaction intermediates were first modeled using Sparta’10 V1.1.0 
software package (Wavefunction Inc.). For each intermediate, a conformational distribution was 
generated through stochastic Monte-Carlo guided searches at the molecular mechanics (MMFF) 
level of theory.71 Conformers within 25 kJ⋅mol−1 of the most stable conformer were subjected to 
geometry optimizations with Gaussian 09.E01 software.72 Calculations using DFT with the 
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hybrid B3LYP functional73,74 and 6-31G(d,p) basis set75 were performed with IEF-PCM model 
solvent (CH3CN).
76 The most stable conformer of each intermediate was then further optimized 
at the B3LYP/6-311++G(2d,2p) level of theory.77,78 In these cases, the Grimme’s empirical 
dispersion correction was applied (D3 version).79 Energy minima were confirmed at 263 K by 
vibrational analysis at the same level of theory, which also allowed for calculation of the Gibbs 
free energies. The 3D structures were rendered using PyMOL. 
 
Ammonium 2,4,5,7,8-Penta-O-acetyl-3-deoxy-α-D-manno-oct-2-ulopyranosylonate (1). 
Crystalline ammonium Kdo48 (1.39 g, 5.45 mmol, 1.0 equiv) was suspended in anhydrous py (55 
mL), and then Ac2O (55 mL) followed by DMAP (6.6 mg, 54 µmol, 0.01 equiv) were added. The 
suspension was stirred for 16 h at rt under Ar after which time the solution was found to be 
homogeneous. The mixture was concentrated under reduced pressure, keeping the temperature 
below 50 °C, and coevaporated with toluene (3×). The residue was purified by silica gel flash 
chromatography (DCM/MeOH 1:0 to 6:4) to give peracetylated Kdo (1, 2.40 g, 95%, ratio α/β > 
95:5) as a yellow oil. The physical and analytical data of 149 were in agreement with those 
published in the literature. 
 
4′-Methoxyphenacyl (Ethyl 4,5,7,8-Tetra-O-acetyl-3-deoxy-2-thio-α,β-D-manno-oct-2-
ulopyranosid)onate (2). Route A: 2-Bromo-4′-methoxyacetophenone (733 mg, 3.20 mmol, 1.6 
equiv), TBAI (111 mg, 301 µmol, 0.15 equiv) and Cs2CO3 (1.33 g, 4.08 mmol, 2.0 equiv) were 
successively added to a solution of peracetylated 1 (900 mg, 2.01 mmol, 1.0 equiv) in anhydrous 
DMF (20 mL). The mixture was stirred for 16 h at rt under Ar. The suspension was filtered over 
Celite, rinsed, and diluted with EtOAc (50 mL). The organic phase was washed with a saturated 
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NH4Cl(aq) solution (25 mL), and H2O (25 mL). The aqueous phase was back extracted with 
EtOAc (25 mL). The combined organic layers were dried over MgSO4, and the solvents were 
concentrated under reduced pressure. The residue was purified by silica gel flash chromatography 
(PE/EtOAc 8:2 to 6:4) to give 4′-methoxyphenacyl (2,4,5,7,8-penta-O-acetyl-3-deoxy-α-D-
manno-oct-2-ulopyranosyl)onate (452 mg, 59%) as a white amorphous powder: [α]D
20 = +84 (c 
0.54, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.91−7.86 (m, 2H, CH-Ar), 6.99−6.95 (m, 2H, CH-
Ar), 5.46 (d, J = 16.0 Hz, 1H, CHHPhen), 5.43−5.38 (m, 2H, H-4, H-5), 5.35 (d, J = 16.0 Hz, 1H, 
CHHPhen), 5.25 (ddd, J6,7 = 9.8 Hz, J7,8b = 3.6 Hz, J7,8a = 2.3 Hz, 1H, H-7), 4.48 (dd, J8a,8b = 12.4 
Hz, J7,8a = 2.2 Hz, 1H, H-8a), 4.18 (dd, J6,7 = 9.9 Hz, J5,6 = 1.0 Hz, 1H, H-6), 4.13 (dd, J8a,8b = 
12.4 Hz, J7,8b = 3.6 Hz, 1H, H-8b), 2.49 (dd, J3ax,3eq = 13.1 Hz, J3ax,4 = 11.8 Hz, 1H, H-3ax), 2.39 
(dd, J3ax,3eq = 13.2 Hz, J3eq,4 = 5.1 Hz, 1H, H-3eq), 2.17, 2.12, 2.05, 2.02, 2.00 (all s, 15H, 5 × 
COCH3); 
13C NMR (100 MHz, CDCl3) δ 189.7 (CH2CO), 170.5, 170.2, 170.1, 169.5, 167.9 (5 × 
COCH3), 165.8 (C-1), 164.3 (C-Ar), 130.1, 130.0 (CH-Ar), 127.0 (C-Ar), 114.2, 114.2 (CH-Ar), 
97.3 (C-2), 69.5 (C-6), 67.3 (C-7), 66.6 (CH2CO), 65.9 (C-4), 63.9 (C-5), 62.1 (C-8), 55.6 
(OCH3), 31.6 (C-3), 20.7, 20.7, 20.6, 20.6, 20.6 (5 × COCH3); HRMS (ESI-TOF) m/z [M + 
NH4]
+ calcd for C27H36NO15 614.2082; found 614.2079; m/z [M + Na]
+ calcd for 
C27H32NaO15 619.1633; found 619.1635. Ethanethiol (12 µL, 170 µmol, 2.0 equiv) was added to 
a solution of the latter phenacyl (50 mg, 84 µmol, 1.0 equiv) in anhydrous DCM (1.7 mL). The 
solution was cooled to 0 °C; then, BF3⋅OEt2 (16 µL, 130 µmol, 1.5 equiv) was added. The 
mixture was stirred for 24 h under Ar, while gradually being warmed to rt. The solution was 
diluted with DCM, and a saturated NaHCO3(aq) solution was added for neutralization. Then, 
iodine was added until a dark color persisted. The excess of iodine was reduced by washing the 
organic phase with a freshly prepared 10% Na2S2O3(aq) solution until the red color disappeared. 
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The solution was poured into a separatory funnel, and the aqueous layer was extracted with 
DCM. The pooled organic phases were dried over MgSO4 and filtered, and the solvents were 
concentrated under reduced pressure. The residue was purified by silica gel flash chromatography 
(PE/EtOAc 1:0 to 5:55) to give thioglycoside 2 (13 mg, 25%) in a 9.0:1.0 β/α anomeric mixture. 
[α]D
20 = +50 (c 0.83, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.93−7.87 (m, 2H, CH-
Ar), 6.95 (m, 2H, CH-Ar), 5.54−5.38 (m, 3H, CHHPhen, H-4, H-5), 5.37−5.28 (m, 1H, 
CHHPhen), 5.28−5.20 (m, 1H, H-7), 4.36−4.33 (m, 2H, H-8a, H-8b), 4.24 (dd, J6,7 = 9.6 Hz, J5,6 
= 1.1 Hz, 1H, H-6), 3.89 (s, 3H, OCH3), 2.91−2.77 (m, 1H, SCHH), 2.74−2.66 (m, 1H, SCHH), 
2.63 (dd, J3eq,3ax = 12.6 Hz, J3eq,4 = 4.2 Hz, 1H, H-3eq), 2.23 (t, J3ax,3eq ≈ J3ax,4 = 12.9 Hz, 1H, H-
3ax), 2.13, 2.03, 1.99, 1.97 (s, 12H, 4 × COCH3), 1.26 (t, J = 7.5 Hz, 3H, SCH2CH3); 
1H NMR 
(400 MHz, CDCl3, α-anomer) δ 7.93−7.87 (m, 2H, CH-Ar), 6.95 (m, 2H, CH-Ar), 5.54−5.38 (m, 
3H, CHHPhen, H-4, H-5), 5.37−5.28 (m, 1H, CHHPhen), 5.28−5.20 (m, 1H, H-7), 4.63 (dd, J8a,8b 
= 12.3 Hz, J7,8a = 2.4 Hz, 1H, H-8a), 4.53 (dd, J6,7 = 9.7 Hz, J5,6 = 1.3 Hz, 1H, H-6), 4.12 (dd, 
J8a,8b = 12.3 Hz, J7,8b = 3.6 Hz, 1H, H-8b), 3.89 (s, 3H, OCH3), 2.91−2.77 (m, 1H, SCHH), 
2.59−2.53 (m, 1H, SCHH), 2.50 (dd, J3ax,3eq = 11.9 Hz, J3ax,4 = 10.6 Hz, 1H, H-3ax), 2.33 (dd, 
J3ax,3eq = 13.7 Hz, J3eq,4 = 4.8 Hz, 1H, H-3eq), 2.10, 2.08, 2.03, 2.01, (s, 12H, 4 × COCH3), 1.26 
(t, J = 7.5 Hz, 3H, SCH2CH3); 
13C NMR (100 MHz, CDCl3, β-anomer) δ 189.3 (CO), 170.8, 
170.6, 169.9, 169.7 (4 × COCH3), 167.8 (C-1), 164.3 (C-Ar), 130.1 (CH-Ar), 126.7 (C-Ar), 114.2 
(CH-Ar), 83.9 (C-2), 72.1 (C-6), 67.9 (C-7), 67.2 (C-4), 66.9 (CH2), 64.4 (C-5), 62.5 (C-8), 55.6 
(OCH3), 32.8 (C-3), 22.6 (SCH2β), 20.8−20.7 (4 × COCH3), 14.1 (SCH2CH3); 
13C NMR (100 
MHz, CDCl3, α-anomer) δ 189.6 (CO), 170.5, 170.4, 169.9, 169.7 (4 × COCH3), 167.7 (C-1), 
164.2 (C-Ar), 130.1 (CH-Ar), 127.0 (C-Ar), 114.2 (CH-Ar), 85.1 (C-2), 68.3 (C-6), 67.6 (C-7), 
67.0 (C-4), 66.6 (CH2), 64.4 (C-5), 61.9 (C-8), 55.6 (OCH3), 31.9 (C-3), 23.5 (SCH2), 20.8−20.7 
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(4 × COCH3), 13.6 (SCH2CH3); HRMS (ESI-TOF) m/z [M + H]
+ calcd for C27H35O13S 599.1793; 
found 599.1789; m/z [M + NH4]
+ calcd for C27H38NO13S 616.2058; found 616.2059; m/z [M + 
Na]+ calcd for C27H34NaO13S 621.1612; found 621.1611. Route B: Ethanethiol (261 µL, 3.53 
mmol, 5.0 equiv) was added to a solution of peracetylated 149 (328 mg, 705 µmol, 1.0 equiv) in 
anhydrous DCE (7.1 mL) at rt under Ar. The solution was cooled to 0 °C and BF3⋅OEt2 (183 µL, 
1.48 mmol, 2.1 equiv) was slowly added. The mixture was refluxed for 40 min and then cooled at 
rt prior adding Et3N (206 µL, 1.48 mmol, 2.1 equiv). The solvents were concentrated under 
reduced pressure to give a residue, which was used in the next step without further purification. 
2-Bromo-4′-methoxyacetophenone (322 mg, 1.41 mmol, 2.0 equiv) was added to a solution of 
the crude thioglycoside in anhydrous DMF (5.6 mL) followed by Cs2CO3 (69 mg, 212 µmol, 0.3 
equiv) and the mixture was stirred for 2 h at rt under Ar. The suspension was filtered over Celite, 
rinsed, and diluted with EtOAc (50 mL). The organic phase was washed with a saturated 
NH4Cl(aq) solution (25 mL) and H2O (25 mL). The combined organic layers were dried over 
MgSO4, and the solvents were concentrated under reduced pressure. The residue was purified by 
silica gel flash chromatography (PE/EtOAc 9:1 to 6:4) to give thioglycoside 6 (190 mg, 45%, two 
steps) as a yellow oil in a ∼1:1 β/α anomeric mixture. Route C: Representative Procedure for the 
Synthesis of Phenacyl Derivatives starting from Benzyl Ester 3. Thioglycoside 3 (965 mg, 1.79 
mmol, 1.0 equiv, ratio β/α 7:1) was dissolved in anhydrous DCE/MeOH (35 mL, 1:4 v/v). The 
solution was degassed with Ar, and 10% Pd/C (965 mg) was added. The suspension was stirred 
under an atmosphere of H2 at rt for 2 h. The mixture was filtered over Celite to remove the 
catalyst, and the cake was rinsed with MeOH and DCM. The solvents were concentrated under 
reduced pressure to give a residue (804 mg, quant.) as a yellow oil, which was used in the next 
step without further purification. 2-Bromo-4′-methoxyacetophenone (61 mg, 268 µmol, 1.5 
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equiv) was added to a solution of crude carboxylic acid (80 mg, 180 µmol) in anhydrous DMF 
(0.9 mL) followed by Cs2CO3 (64 mg, 196 µmol, 1.1 equiv). The mixture was stirred for 2 h at rt 
under Ar. The suspension was filtered over Celite, rinsed, and diluted with EtOAc (100 mL). The 
organic phase was washed with a saturated NH4Cl(aq) solution (50 mL) and H2O (50 mL). The 
combined organic layers were dried over MgSO4, and the solvents were concentrated under 
reduced pressure. The residue was purified by silica gel flash chromatography (PE/EtOAc 1:0 to 
6:4) to give thioglycoside 2 (81 mg, 76%) as a colorless oil in a 7:1 β/α anomeric mixture.  
 
Benzyl (Ethyl 4,5,7,8-Tetra-O-acetyl-3-deoxy-2-thio-α,β-D-manno-oct-2-ulopyranosid)onate (3).   
Route A: BnBr (848 µL, 7.09 mmol, 2.2 equiv) followed by Cs2CO3 (420 mg, 1.29 mmol, 0.4 
equiv) were added to a solution of peracetylated 149 (1.5 g, 3.22 mmol, 1.0 equiv) in anhydrous 
DMF (16 mL). The mixture was stirred for 2 h at rt under Ar. The suspension was filtered over 
Celite, rinsed, and diluted with EtOAc (50 mL). The organic phase was washed with a saturated 
NH4Cl(aq) solution (25 mL) and H2O (25 mL). The combined organic layers were dried over 
MgSO4, and the solvents were concentrated under reduced pressure. The residue was purified by 
silica gel flash chromatography (PE/EtOAc 8:2 to 7:3) to give benzyl (2,4,5,7,8-penta-O-acetyl-
3-deoxy-α-D-manno-oct-2-ulopyranosyl)onate (1.26 g, 73%) as a white foam. The physical and 
analytical data of 380 were in agreement with those published in the literature. Ethanethiol (286 
µL, 3.86 mmol, 2.0 equiv) was added to a solution of the latter benzyl ester (1.04 g, 1.93 mmol, 
1.0 equiv) in anhydrous DCE (10 mL). The solution was cooled to 0 °C; then, BF3⋅OEt2 (357 µL, 
2.90 mmol, 1.5 equiv) was slowly added. The mixture was stirred for 2 h under Ar, while 
gradually being warmed to rt. The solution was diluted with DCM, and a saturated NaHCO3(aq) 
solution was added for neutralization. Then, iodine was added until a dark color persisted. The 
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excess of iodine was reduced by washing the organic phase with a freshly prepared 10% 
Na2S2O3(aq) solution until the red color disappeared. The solution was poured into a separatory 
funnel, and the aqueous layer was extracted with DCM. The pooled organic phases were dried 
over MgSO4 and filtered, and the solvents were concentrated under reduced pressure. The residue 
was purified by silica gel flash chromatography (PE/EtOAc 85:15 to 75:25) to give thioglycoside 
3 (956 mg, 92%) as a 7.0:1.0 β/α anomeric mixture. The physical and analytical data of 310 were 
in agreement with those published in the literature. Route B: Ethanethiol (307 µL, 4.14 mmol, 5.0 
equiv) was added to a solution a peracetylated 149 (386 mg, 829 µmol, 1.0 equiv) in anhydrous 
DCE (8.0 mL) at rt under Ar. The solution was cooled to 0 °C and BF3⋅OEt2 (95 µL, 770 µmol, 
2.0 equiv) was slowly added. The mixture was refluxed for 40 min and then cooled at rt prior 
adding Et3N (230 µL, 4.15 mmol, 5.0 equiv). The solvents were concentrated under reduced 
pressure to give a residue, which was used in the next step without further purification. Benzyl 
bromide (218 µL, 1.82 mmol, 2.2 equiv) was added to a solution of the crude thioglycoside in 
anhydrous DMF (4.1 mL) followed by Cs2CO3 (108 mg, 332 µmol, 0.4 equiv) and the mixture 
was stirred for 2 h at rt under Ar. The suspension was filtered over Celite, rinsed, and diluted with 
EtOAc (50 mL). The organic phase was washed with a saturated NH4Cl(aq) solution (25 mL) and 
H2O (25 mL). The combined organic layers were dried over MgSO4, and the solvents were 
concentrated under reduced pressure. The residue was purified by silica gel flash chromatography 
(PE/EtOAc 9:1 to 6:4) to give thioglycoside 3 (224 mg, 50%, two steps) as a yellow oil in a ∼1:1 
β/α anomeric mixture. 
 
4′-Methoxyphenacyl (Fluoride 4,5,7,8-Tetra-O-acetyl-3-deoxy-α-D-manno-oct-2-
ulopyranosyl)onate (4). HF.py (5.0 mL, ca. 70% HF, ca. 30% py) was added to a solution of 
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peracetylated 149 (675 mg, 1.59 mmol, 1.0 equiv) in anhydrous DCM (16 mL) at 0 °C under Ar. 
The mixture was stirred for 3 h, while gradually being warmed to rt. Ice-cold water (10 mL) was 
added and the phases were mixed and left separated. The aqueous phase was acidified with 10% 
HCl(aq) until pH ∼3 and extracted with DCM (3 × 10 mL). The combined organic layers were 
dried over MgSO4, filtered, and the solvents were concentrated under reduced pressure to give a 
crude fluoride (391 mg, 63%) as a colorless oil after being placed under high vacuum for 3 h. A 
portion of the latter compound (191 mg, 450 µmol, 1.0 equiv) was dissolved in anhydrous DMF 
(2.3 mL). 2-Bromo-4′-methoxyacetophenone (226 mg, 989 µmol, 2.2 equiv) followed by Cs2CO3 
(59 mg, 180 µmol, 0.4 equiv) were added and the mixture was stirred for 2 h at rt under Ar. The 
suspension was filtered over Celite, rinsed, and diluted with EtOAc (50 mL). The organic phase 
was washed with a saturated NH4Cl(aq) solution (25 mL) and H2O (25 mL). The combined 
organic layers were dried over MgSO4, and the solvents were concentrated under reduced 
pressure. The residue was purified by silica gel flash chromatography (PE/EtOAc 1:0 to 6:4) to 
give α-fluoride 4 (192 mg, 77%) as a yellow oil. [α]D
20 = +35 (c 0.75, CHCl3); 
1H NMR (400 
MHz, CDCl3) δ 7.91–7.87 (m, 2H, CH-Ar), 7.00–6.96 (m, 2H, CH-Ar), 5.51–5.44 (m, 3H, H-5, 
CH2Phen), 5.39 (ddd, J3ax,4 = 12.1 Hz, J4,5 = 5.4 Hz, J3eq,4 = 3.0 Hz, 1H, H-4), 5.26 (dddd, J6,7 = 
9.6 Hz, J7,8b = 4.4 Hz, J7,8a = 2.3 Hz, J5,7 = 0.8 Hz, 1H, H-7), 4.51 (dd, J8a,8b = 12.4 Hz, J7,8a = 2.3 
Hz, 1H, H-8a), 4.42 (dd, J6,7 = 9.7 Hz, J5,6 = 1.3 Hz, 1H, H-6), 4.17 (dd, J8a,8b = 12.4 Hz, J7,8b = 
4.4 Hz, 1H, H-8b), 3.89 (s, 3H, OCH3), 2.63–2.41 (m, 2H, H-3ax, H-3eq), 2.12, 2.09, 2.02, 2.02 
(all s, 12H, 4 × COCH3); 
13C NMR (100 MHz, CDCl3) δ 188.9 (COPhen), 170.7, 170.5, 170.0, 
169.8 (4 × COCH3), 164.3 (C-1, 
2
JC1,F = 41.8 Hz), 130.2 (2 × CH-Ar), 126.9 (C-Ar), 114.4 (2 × 
CH-Ar), 108.3 (C-2, 1JC2,F = 232 Hz), 70.7 (C-6, 
3
JC6,F = 1.5 Hz), 67.5 (C-7), 67.1 (CH2Phen), 
65.6 (C-4), 64.1 (C-5), 62.2 (C-8), 55.7 (OCH3), 30.7 (C-3, 
2
JC3,F = 27.3 Hz), 20.84 (2C), 20.78, 
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20.77 (4 × COCH3); 
19F (376 MHz, CDCl3) δ 376.5 (dd, 
3
JF,H3ax = 34.6 Hz, 
3
JF,3eq = 6.0 Hz); 
HRMS (ESI-TOF) m/z [M + Na]+ calcd for C25H29FNaO13 579.1484; found 579.1494. 
 
Benzyl (Fluoride 4,5,7,8-Tetra-O-acetyl-3-deoxy-α-D-manno-oct-2-ulopyranosyl)onate (5). 
HF.py (5.0 mL, ca. 70% HF, ca. 30% py) was added to a solution of peracetylated 149 (675 mg, 
1.59 mmol, 1.0 equiv) in anhydrous DCM (16 mL) at 0 °C under Ar. The mixture was stirred for 
3 h, while gradually being warmed to rt. Ice-cold water (10 mL) was added and the phases were 
mixed and left separated. The aqueous phase was acidified with 10% HCl(aq) until pH ∼3 and 
extracted with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, 
and the solvents were concentrated under reduced pressure to give a crude fluoride (391 mg, 
63%) as a colorless oil after being placed under high vacuum for 3 h. A portion of the latter 
compound (191 mg, 450 µmol, 1.0 equiv) was dissolved in anhydrous DMF (2.3 mL). Benzyl 
bromide (118 µL, 989 µmol, 2.2 equiv) followed by Cs2CO3 (59 mg, 180 µmol, 0.4 equiv) were 
added and the mixture was stirred for 2 h at rt under Ar. The suspension was filtered over Celite, 
rinsed, and diluted with EtOAc (50 mL). The organic phase was washed with a saturated 
NH4Cl(aq) solution (25 mL) and H2O (25 mL). The combined organic layers were dried over 
MgSO4, and the solvents were concentrated under reduced pressure. The residue was purified by 
silica gel flash chromatography (PE/EtOAc 1:0 to 55:45) to give α-fluoride 5 (159 mg, 71%) as a 
colorless oil. [α]D
20 = +50 (c 1.9, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.44–7.33 (m, 5H, CH-
Ar), 5.44–5.42 (m, 1H, H-5), 5.33 (ddd, J3ax,4 = 11.9 Hz, J4,5 = 5.4 Hz, J3eq,4 = 3.0 Hz, 1H, H-4), 
5.29 (d, J = 10.1 Hz, 1H, CHHPh), 5.28 (d, J = 9.4 Hz, 1H, CHHPh), 5.21 (dddd, J6,7 = 9.7 Hz, 
J7,8b = 4.4 Hz, J7,8a = 2.3 Hz, J5,7 = 1.0 Hz, 1H, H-7), 4.49 (dd, J8a,8b = 12.3 Hz, J7,8a = 2.3 Hz, 1H, 
H-8a), 4.38 (dd, J6,7 = 9.7 Hz, J5,6 = 1.3 Hz, 1H, H-6), 4.13 (dd, J8a,8b = 12.3 Hz, J7,8b = 4.4 Hz, 
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1H, H-8b), 2.44–2.23 (m, 2H, H-3ax, H-3eq), 2.10, 2.07, 2.01, 2.00 (all s, 12H, 4 × COCH3); 
13C 
NMR (100 MHz, CDCl3) δ 170.7, 170.4, 169.9, 169.8 (4 × COCH3), 164.4 (C-1, 
2
JC1,F = 29.7 
Hz), 134.7 (C-Ar), 128.9, 128.8, 128.3 (5 × CH-Ar), 108.1 (C-2, 1JC2,F = 232 Hz), 70.7 (C-6, 
3
JC6,F = 2.2 Hz), 68.2 (CH2Ph), 67.4 (C-7), 65.7 (C-4), 64.1 (C-5), 62.2 (C-8), 30.3 (C-3, 
2
JC3,F = 
27.6 Hz), 20.82 (2C), 20.77, 20.7 (4 × COCH3); 
19F NMR (376 MHz, CDCl3) δ 376.5 (dd, 
3
JF,H3ax 
= 34.1 Hz, 3JF,H3eq = 5.4 Hz); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for 
C23H27FNaO11 521.1430; found 521.1421; m/z [2M + Na]




ulopyranosid)onate (6). Thioglycoside 3 (β/α 7:1, 163 mg, 303 µmol, 1.0 equiv) was reacted 
according to the representative procedure for the synthesis of phenacyl derivatives starting from 
benzyl ester 3 and gave thioglycoside 6 (147 mg, 81%, two steps, β/α 7:1) as a white foam. 
[α]D
20 = +74 (c 0.23, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.49–7.45 (m, 2H, CH-
Ar), 7.44–7.39 (m, 1H, CH-Ar), 7.20–7.16 (m, 1H, CH-Ar), 5.54 (d, J = 16.2 Hz, 1H, 
CHHPhen), 5.48–5.41 (m, 2H, H-5, H-4), 5.37 (d, J = 16.2 Hz, 1H, CHHPhen), 5.23 (ddd, J6,7 = 
9.6 Hz, J7,8b = 5.2 Hz, J7,8a = 2.9 Hz, 1H, H-7), 4.36–4.33 (m, 2H, H-8a, H-8b), 4.22 (d, J6,7 = 9.6 
Hz, J5,6 = 1.0 Hz, 1H, H-6), 3.87 (s, 3H, OCH3), 2.91–2.81 (m, 1H, SCHH), 2.73–2.66 (m, 1H, 
SCHH), 2.63 (ddd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.2 Hz, J3eq,5 = 0.9 Hz, 1H, H-3eq), 2.24 (t, J3ax,3eq ≈ 
J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.13, 2.03, 2.00, 1.98 (all s, 12H, 4 × COCH3), 1.27 (t, J = 7.6 Hz, 
3H, SCH2CH3);
 13C NMR (100 MHz, CDCl3, β-anomer) δ 190.9 (COPhen), 170.9, 169.9, 169.8, 
167.9 (4 × COCH3), 167.9 (C-1), 160.3, 135.2 (2 × C-Ar), 130.1, 121.0, 120.3, 112.1 (4 × CH-
Ar), 84.1 (C-2), 72.3 (C-6), 68.1 (C-7), 67.4 (C-4), 67.3 (CH2Phen), 64.5 (C-5), 62.7 (C-8), 55.7 
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(OCH3), 33.0 (C-3), 23.6 (SCH2), 20.9–20.8 (4 × COCH3), 14.2 (SCH2CH3); HRMS (ESI-TOF) 
m/z [M + Na]+ calcd for C27H34NaO13S 621.1612; found 621.1618; m/z [2M + Na]
+ calcd for 
C54H68NaO26S2 1219.3332; found 129.3336.  
 
2′-Methoxyphenacyl (Ethyl 4,5,7,8-Tetra-O-acetyl-3-deoxy-2-thio-α,β-D-manno-oct-2-
ulopyranosid)onate (7). Thioglycoside 3 (β/α 7:1, 150 mg, 279 µmol, 1.0 equiv) was reacted 
according to the representative procedure for the synthesis of phenacyl derivatives starting from 
benzyl ester 3 and gave thioglycoside 7 (134 mg, 80%, two steps, β/α 7:1) as a white foam. 
[α]D
20 = +52 (c 0.7, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 8.03–8.00 (m, 1H, CH-
Ar), 7.58–7.53 (m, 1H, CH-Ar), 7.09–6.99 (m, 2H, CH-Ar), 5.48–5.43 (m, 2H, H-5, H-4), 5.41 
(d, J = 17.1 Hz, 1H, CHHPhen), 5.32 (d, J = 17.1 Hz, 1H, CHHPhen), 5.26–5.20 (m, 1H, H-7), 
4.36–4.34 (m, 2H, H-8a, H-8b), 4.26 (dd, J6,7 = 9.6 Hz, J5,6 = 1.1 Hz, 1H, H-6), 3.98 (s, 3H, 
OCH3), 2.93–2.83 (m, 1H, SCHH), 2.77–2.67 (m, 1H, SCHH), 2.63 (ddd, J3ax,3eq = 12.5 Hz, J3eq,4 
= 4.6 Hz, J3eq,5 = 1.0 Hz, 1H, H-3eq), 2.22 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.13, 2.03, 
1.99 (all s, 12H, 4 × COCH3), 1.27 (t, J = 7.5 Hz, 3H, SCH2CH3);
 13C NMR (100 MHz, CDCl3, 
β-anomer) δ 191.6 (COPhen), 170.9, 170.7, 170.0, 169.8 (4 × COCH3), 168.0 (C-1), 159.8 (C-
Ar), 135.4, 131.5 (2 × CH-Ar), 123.9 (C-Ar), 121.3, 111.7 (2 × CH-Ar), 84.2 (C-2), 72.2 (C-6), 
71.2 (CH2Phen), 68.1 (C-7), 67.4 (C-4), 64.6 (C-5), 62.8 (C-8), 55.8 (OCH3), 33.0 (C-3), 23.6 
(SCH2CH3), 20.9–20.8 (4 × COCH3), 14.2 (SCH2CH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd 
for C27H34NaO13S 621.1612; found 621.1622; m/z [2M + Na]
+ calcd for 
C54H68NaO26S2 1219.3332; found 1219.3340.  
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Phenacyl (Ethyl 4,5,7,8-Tetra-O-acetyl-3-deoxy-2-thio-α,β-D-manno-oct-2-ulopyranosid)onate 
(8). Thioglycoside 3 (β/α 7:1, 174 mg, 322 µmol, 1.0 equiv) was reacted according to the 
representative procedure for the synthesis of phenacyl derivatives starting from benzyl ester 3 and 
gave thioglycoside 8 (129 mg, 70%, two steps, β/α 7:1) as a white foam. [α]D
20 = +58 (c 0.35, 
CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.95–7.91 (m, 2H, CH-Ar), 7.67–7.62 (m, 1H, 
CH-Ar), 7.55–7.49 (m, 2H, CH-Ar), 5.55 (d, J = 16.2 Hz, 1H, CHHPhen), 5.48–5.43 (m, 2H, H-
5, H-4), 5.39 (d, J = 16.2 Hz, 1H, CHHPhen), 5.23 (ddd, J6,7 = 9.5 Hz, J7,8b = 3.9 Hz, J7,8a = 2.8 
Hz, 1H, H-7), 4.36–433 (m, 2H, H-8a, H-8b), 4.22 (dd, J6,7 = 9.6 Hz, J5,6 = 1.0 Hz, 1H, H-6), 
2.91–2.81 (m, 1H, SCHH), 2.73–2.65 (m, 1H, SCHH), 2.64 (ddd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.2 
Hz, J3eq,5 = 1.0 Hz, 1H, H-3eq), 2.24 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.13, 2.03, 2.00, 
1.98 (all s, 12H, 4 × COCH3), 1.27 (t, J = 7.6 Hz, 3H, SCH2CH3);
 13C NMR (100 MHz, CDCl3, 
β-anomer) δ 191.1 (COPhen), 170.9, 170.7, 170.0, 169.8 (4 × COCH3), 167.9 (C-1), 134.4 (CH-
Ar), 133.9 (C-Ar), 129.1 (2C), 127.9 (2C, 4 × CH-Ar), 84.1 (C-2), 72.3 (C-6), 68.1 (C-7), 67.4 
(C-4), 67.2 (CH2Phen), 64.5 (C-5), 62.7 (C-8), 33.0 (C-3), 23.6 (SCH2), 20.90, 20.89, 20.85, 
20.80 (4 × COCH3), 14.2 (SCH2CH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for C26H32NaO12S 
591.1507; found 591.1508; m/z [2M + Na]+ calcd for C52H64NaO24S2 1159.3121; found 
1159.3117.  
 
General Procedure for Glycosylation with Thioglycoside Donors. Freshly activated powdered 
4 Å molecular sieves (4 mg⋅mg–1 of acceptor) was added to a solution of thioglycoside 2 or 3 (1 
equiv), glycosyl acceptor 9–14 (1.4–2.0 equiv), and NIS (2.0 equiv) in anhydrous CH3CN (20 
mL⋅mmol–1). The mixture was stirred for 1 h at rt under Ar. Then, the suspension was cooled to –
10 °C; the flask was protected from light, and AgOTf (1.0 equiv) was added in one portion. The 
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mixture was stirred for 30 min at –10 °C under Ar. Et3N (2.0 equiv) was added to quench the 
reaction. The suspension was filtered over Celite, rinsed with DCM, and the solvents were 
concentrated under reduced pressure. The residue was purified by silica gel flash chromatography 
to give a mixture of Kdo glycoside anomers. 
 
General Procedure for Glycosylation with Fluoride Donors. Freshly activated powdered 4 Å 
molecular sieves (4 mg⋅mg–1 of acceptor) was added to a solution of fluoride 4 or 5 (1 equiv) and 
acceptor 9 (2.0 equiv) in anhydrous DCM (25 mL⋅mmol–1). The mixture was stirred for 1 h at rt 
under Ar. Then, the suspension was cooled to 0 °C and BF3⋅OEt2 (6.0 equiv) was slowly added. 
The mixture was stirred from 0 °C to rt for 2 h or until TLC had showed complete conversion of 
the donor. Then, the suspension was filtered over Celite, rinsed and diluted with DCM. The 
organic phase was washed with a saturated NaHCO3(aq) solution and brine. The organic phase 
was dried over MgSO4, filtered, and the solvents were concentrated under reduced pressure. The 
residue was purified by silica gel flash chromatography to give a mixture of Kdo glycoside 
anomers together with glycal. 
 
4′-Methoxyphenacyl [2-(5-Amino-N-benzyloxycarbonyl-1-pentyl) 4,5,7,8-Tetra-O-acetyl-3-
deoxy-α,β-D-manno-oct-2-ulopyranosid]onate (15β and 15α) and 4′-Methoxyphenacyl 4,5,7,8-
Tetra-O-acetyl-2,6-anhydro-3-deoxy-D-manno-oct-2-enosonate (16). Thioglycoside 2 (750 mg, 
1.25 mmol, 1.0 equiv, β/α ∼1:1) and acceptor 9 (595 mg, 2.51 mmol, 2.0 equiv) were reacted 
according to the general procedure for glycosylation with thioglycoside donors and gave 15 (827 
mg, 84%, β/α 7.9:1.0) as a colorless oil. [α]D
20 = –11 (c 1.4, CHCl3);
 1H NMR (400 MHz, CDCl3, 
β-anomer) δ 7.92–7.86 (m, 2H, CH-Ar), 7.38–7.28 (m, 5H, CH-Ar), 6.98–6.92 (m, 2H, CH-Ar), 
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5.44 (d, J = 16.0 Hz, 1H, CHHPhen), 5.40–5.38 (m, 1H, H-5), 5.38 (d, J = 16.0 Hz, 1H, 
CHHPhen), 5.32 (ddd, J3ax,4 = 13.0 Hz, J3eq,4 = 4.6 Hz, J4,5 = 3.0 Hz, 1H, H-4), 5.21 (ddd, J6,7 = 
13.0 Hz, J7,8a = 4.6 Hz, J7,8b = 3.0 Hz, 1H, H-7), 5.11–5.07 (m, 2H, COCH2Ph), 5.02–4.93 (m, 
1H, NHCbz), 4.42–4.29 (m, 3H, H-8a, H-8b, H-6), 3.82 (dt, J = 9.2, 6.3 Hz, 1H, H-1a′), 3.52 (dt, 
J = 9.2, 6.3 Hz, 1H, H-1b′), 3.24–3.18 (m, 2H, H-5ab′), 2.52 (dd, J3eq,3ax = 12.5 Hz, J3eq,4 = 4.7 
Hz, 1H, H-3eq), 2.16 (t, J3eq,3ax ≈ J3ax,4 ≈ 12.8 Hz, 1H, H-3ax), 2.11, 2.02, 2.00, 1.99 (all s, 12H, 4 
× COCH3), 1.68–1.51 (m, 4H, H-2ab′, H-4ab′), 1.47–1.37 (m, 2H, H-3ab′); 
13C NMR (100 MHz, 
CDCl3, β-anomer) δ 189.1 (COPhen), 170.8, 170.5, 169.9, 169.7 (4 × COCH3), 167.5 (C-1, 
3
JC1,H3ax = 5.2 Hz), 164.3 (COCH2Ph), 156.5 (C-Ar), 136.7 (C-Ar), 130.1, 128.5, 128.0 (CH-Ar), 
126.7 (C-Ar), 114.2 (CH-Ar), 99.5 (C-2), 70.8 (C-6), 68.1 (C-7), 67.2 (C-4), 66.6, 66.5 (2 × 
CH2), 64.4 (C-1′), 64.3 (C-5), 62.7 (C-8), 55.6 (OCH3), 40.9 (C-5′), 32.6 (C-3), 29.7, 29.1 (C-2′, 
C-4′), 23.1 (C-3′), 20.80, 20.75 (2C), 20.73 (4 × COCH3); HRMS (ESI-TOF) m/z [M + H]
+ calcd 
for C38H48NO16 774.2968; found 774.2969; m/z [M + NH4]
+ calcd for C38H51N2O16 791.3233; 
found 791.3237; m/z [M + Na]+ calcd for C38H47NNaO16 796.2787; found 796.2788. Analytical 
data for glycal 16: [α]D
20 = +33 (c 2.7, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.93–7.89 (m, 2H, 
CH-Ar), 7.00–6.95 (m, 2H, CH-Ar), 6.05 (t, J3,4 ≈ J3,5 ≈ 2.0 Hz, 1H, H-3), 5.76 (ddd, J4,5 = 4.5 
Hz, J3,4 = 2.2 Hz, J4,6 = 1.3 Hz, 1H, H-4), 5.51 (ddd, J4,5 = 4.5 Hz, J3,5 = 1.7 Hz, J5,6 = 1.1 Hz, 1H, 
H-5), 5.45 (d, J = 16.0 Hz, 1H, CHHPhen), 5.39 (d, J = 16.0 Hz, 1H, CHHPhen), 5.29 (ddd, J6,7 = 
9.7 Hz, J7,8b = 3.9 Hz, J7,8a = 2.5 Hz, 1H, H-7), 4.63 (dd, J8a,8b = 12.4 Hz, J7,8a = 2.5 Hz, 1H, H-
8a), 4.41 (dt, J6,7 = 9.7 Hz, J5,6 ≈ J4,6 ≈ 1.1 Hz, 1H, H-6), 4.24 (dd, J8a,8b = 12.4 Hz, J7,8b = 3.9 Hz, 
1H, H-8b), 2.11, 2.09, 2.05, 2.04 (all s, 12H, 4 × COCH3); 
13C NMR (100 MHz, CDCl3) δ 189.8 
(COPhen), 170.7, 170.5, 170.2, 169.6 (4 × COCH3), 164.4 (C-Ar), 160.6 (C-1), 144.3 (C-2), 
130.3 (2 × CH-Ar), 128.7 (C-Ar), 114.3 (2 × CH-Ar), 108.8 (C-3), 73.6 (C-6), 67.5 (C-7), 66.6 
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(CH2Phen), 64.9 (C-4), 62.0 (C-8), 60.9 (C-5), 55.7 (OCH3), 20.9, 20.8, 20.74, 20.70 (4 × 
COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for C25H28NaO13 559.1422; found 559.1445. 
 
Benzyl [2-(5-Amino-N-benzyloxycarbonyl-1-pentyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-
manno-oct-2-ulopyranosid]onate (17β and 17α) and Benzyl 4,5,7,8-Tetra-O-acetyl-2,6-anhydro-
3-deoxy-D-manno-oct-2-enosonate (18). Thioglycoside 3 (1.14 g, 2.10 mmol, 1.0 equiv, β/α 7:1) 
and acceptor 9 (998 mg, 4.21 mmol, 2.0 equiv) were reacted according to the general procedure 
for glycosylation with thioglycoside donors and gave 17β (1.21 g, 81%) and 17α (192 mg, 13%) 
both as yellow oils (β/α 6.3:1.0). The physical and analytical data of 17β and 17α were in 
agreement with those published in the literature.10 Analytical data for glycal 18: [α]D
20 = +1.3 (c 
1.9, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.41–7.34 (m, 5H, CH-Ar), 5.92 (t, J3,4 ≈ J3,5 ≈ 2.0 
Hz, 1H, H-3), 5.73–5.70 (m, 1H, H-4), 5.49–5.46 (m, 1H, H-5), 5.30–5.24 (m, 3H, H-7, CH2Ph), 
4.63 (dd, J8a,8b = 12.3 Hz, J7,8a = 2.3 Hz, 1H, H-8a), 4.36 (br d, J6,7 = 9.7 Hz, 1H, H-6), 4.24 (dd, 
J8a,8b = 12.3 Hz, J7,8b = 4.0 Hz, 1H, H-8b), 2.09 (s, 6H, 2 × COCH3), 2.04, 2.03 (all s, 6H, 2 × 
COCH3); 
13C NMR (100 MHz, CDCl3) δ 170.6, 170.5, 170.2, 169.6 (4 × COCH3), 160.9 (C-1), 
144.7 (C-2), 135.3 (C-Ar), 128.8, 128.7, 128.5 (5 × CH-Ar), 107.9 (C-3), 73.4 (C-6), 67.39 (C-7), 
67.37 (CH2Ph), 64.8 (C-4), 62.0 (C-8), 60.8 (C-5), 20.9, 20.8, 20.75, 20.68 (4 × COCH3); HRMS 
(ESI-TOF) m/z [M + Na]+ calcd for C23H26NaO11 501.1367; found 501.1380. 
 
3′-Methoxyphenacyl [2-(5-Amino-N-benzyloxycarbonyl-1-pentyl) 4,5,7,8-Tetra-O-acetyl-3-
deoxy-α,β-D-manno-oct-2-ulopyranosid]onate (19). Thioglycoside 6 (45 mg, 75 µmol, 1.0 equiv, 
β/α 7:1) and acceptor 9 (31 mg, 110 µmol, 1.5 equiv) were reacted according to the general 
procedure for glycosylation with thioglycoside donors and gave 19 (42 mg, 73%, β/α 6.6:1.0) as 
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a yellow oil. [α]D
20 = +31 (c 5.7, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.49–7.29 
(m, 8H, CH-Ar), 7.19–7.14 (m, 1H, CH-Ar), 5.49 (d, J = 16.2 Hz, 1H, CHHPhen), 5.42 (d, J = 
16.2 Hz, 1H, CHHPhen), 5.41–5.39 (m, 1H, H-5), 5.31 (ddd, J3ax,4 = 13.0 Hz, J3eq,4 = 4.6 Hz, J4,5 
= 3.1 Hz, 1H, H-4), 5.22 (ddd, J6,7 = 9.5 Hz, J7,8b = 4.8 Hz, J7,8a = 2.4 Hz, 1H, H-7), 5.15–5.05 
(m, 3H, CH2Ph, NHCbz), 4.42–4.30 (m, 3H, H-8a, H-8b, H-6), 3.88–3.79 (m, 1H, H-1a′), 3.86 (s, 
3H, OCH3), 3.56–3.48 (m, 1H, H-1b′), 3.24–3.17 (m, 2H, H-5ab′), 2.53 (dd, J3ax,3eq = 12.5 Hz, 
J3eq,4 = 4.6 Hz, 1H, H-3eq), 2.17 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.12, 2.03, 2.00 (all s, 
12H, 4 × COCH3), 1.67–1.50, 1.47–1.38 (all m, 6H, H-2′, H-3′, H-4′);
 13C NMR (100 MHz, 
CDCl3, β-anomer) δ 190.7 (COPhen), 170.9, 170.6, 170.0, 169.9 (4 × COCH3), 167.5 (C-1), 
160.1, 136.8, 135.1 (3 × C-Ar), 130.1, 128.6, 128.1, 120.9, 120.3, 112.1 (CH-Ar), 99.5 (C-2), 
70.9 (C-6), 68.2 (C-7), 67.3 (C-4), 67.1 (CH2Phen), 66.6 (CH2Ph), 64.5 (C-1′), 64.3 (C-5), 62.8 
(C-8), 55.6 (OCH3), 41.0 (C-5′), 32.7 (C-3), 29.8, 29.2, 23.1 (C-2′, C-3′, C-4′), 20.9–20.8 (4 × 
COCH3); HRMS (ESI-TOF) m/z [M + H]
+ calcd for C38H48NO16 774.2968; found 774.2973; m/z 
[M + Na]+ calcd for C38H47NNaO16 796.2787; found 796.2792; m/z [2M + Na]
+ calcd for 
C76H94N2NaO32 1569.5682; found 1569.5688.  
 
2′-Methoxyphenacyl [2-(5-Amino-N-benzyloxycarbonyl-1-pentyl) 4,5,7,8-Tetra-O-acetyl-3-
deoxy-α,β-D-manno-oct-2-ulopyranosid]onate (20). Thioglycoside 7 (45 mg, 75 µmol, 1.0 equiv, 
β/α 7:1) and acceptor 9 (31 mg, 110 µmol, 1.5 equiv) were reacted according to the general 
procedure for glycosylation with thioglycoside donors and gave 20 (47 mg, 80%, β/α 4.6:1.0) as 
a colorless oil. [α]D
20 = +31 (c 4.6, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 8.00–7.97 
(m, 1H, CH-Ar), 7.58–7.52 (m, 1H, CH-Ar), 7.37–7.29 (m, 5H, CH-Ar), 7.06–6.99 (m, 2H, CH-
Ar), 5.40–5.38 (m, 1H, H-5), 5.36–5.33 (m, 2H, CH2Phen), 5.32 (ddd, J3ax,4 = 12.5 Hz, J3eq,4 = 5.3 
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Hz, J4,5 = 3.1 Hz, 1H, H-4), 5.22 (ddd, J6,7 = 9.5 Hz, J7,8b = 5.0 Hz, J7,8a = 2.2 Hz, 1H, H-7), 5.10–
5.07 (m, 2H, CH2Ph), 4.41 (dd, J8a,8b = 12.3 Hz, J7,8a = 2.1 Hz, 1H, H-8a), 4.37 (dd, J6,7 = 9.6 Hz, 
J5,6 = 1.1 Hz, 1H, H-6), 4.32 (dd, J8a,8b = 12.3 Hz, J7,8b = 5.1 Hz, 1H, H-8b), 3.97 (s, 3H, OCH3), 
3.86–3.80 (m, 1H, H-1a′), 3.59–3.52 (m, 1H, H-1b′), 3.25–3.17 (m, 2H, H-5ab′), 2.52 (dd, J3ax,3eq 
= 12.5 Hz, J3eq,4 = 4.8 Hz, 1H, H-3eq), 2.15 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.11, 2.02, 
2.00 (all s, 12H, 4 × COCH3), 1.68–1.50, 1.47–1.37 (all m, 6H, H-2′, H-3′, H-4′);
 13C NMR (100 
MHz, CDCl3, β-anomer) δ 191.3 (COPhen), 171.0, 170.7, 170.1, 169.9 (4 × COCH3), 167.7 (C-
1), 159.7, 135.4, 123.8 (3 × C-Ar), 135.4, 131.4, 128.6, 128.2, 128.1, 121.3, 111.7 (CH-Ar), 99.6 
(C-2), 71.0 (CH2Phen), 70.8 (C-6), 68.3 (C-7), 67.3 (C-4), 66.6 (CH2Ph), 64.6 (C-1′), 64.4 (C-5), 
62.9 (C-8), 55.7 (OCH3), 41.1 (C-5′), 32.8 (C-3), 29.8, 29.2, 23.2 (C-2′, C-3′, C-4′), 20.9–20.8 (4 
× COCH3); HRMS (ESI-TOF) m/z [M + H]
+ calcd for C38H48NO16 774.2968; found 774.2985; 
m/z [M + Na]+ calcd for C38H47NNaO16 796.2787; found 796.2804; m/z [2M + Na]
+
 calcd for 
C76H94N2NaO32 1569.5682: found 1569.5711. 
 
Phenacyl [2-(5-Amino-N-benzyloxycarbonyl-1-pentyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-
manno-oct-2-ulopyranosid]onate (21). Thioglycoside 8 (45 mg, 75 µmol, 1.0 equiv, β/α 7:1) and 
acceptor 9 (31 mg, 110 µmol, 1.5 equiv) were reacted according to the general procedure for 
glycosylation with thioglycoside donors and gave 21 (45 mg, 77%, β/α 6.2:1.0) as a colorless oil. 
[α]D
20 = +36 (c 4.4, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.94–7.89 (m, 2H, CH-
Ar), 7.66–7.60 (m, 1H, CH-Ar), 7.53–7.47 (m, 2H, CH-Ar), 7.38–7.29 (m, 5H, CH-Ar), 5.50 (d, 
J = 16.2 Hz, 1H, CHHPhen), 5.43 (d, J = 16.2 Hz, 1H, CHHPhen), 5.41–5.38 (m, 1H, H-5), 5.32 
(ddd, J3ax,4 = 13.0 Hz, J3eq,4 = 4.6 Hz, J4,5 = 3.0 Hz, 1H, H-4), 5.22 (ddd, J6,7 = 9.6 Hz, J7,8b = 4.9 
Hz, J7,8a = 2.3 Hz, 1H, H-7), 5.11–5.06 (m, 2H, CH2Ph), 5.03 (t, J = 5.8 Hz, 1H, NHCbz), 4.42–
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4.31 (m, 3H, H-8a, H-8b, H-6), 3.86–3.79 (m, 1H, H-1a′), 3.55–3.49 (m, 1H, H-1b′), 3.25–3.17 
(m, 2H, H-5ab′), 2.53 (dd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.7 Hz, 1H, H-3eq), 2.17 (t, J3ax,3eq ≈ J3ax,4 ≈ 
12.5 Hz, 1H, H-3ax), 2.11, 2.03, 2.00, 1.99 (all s, 12H, 4 × COCH3), 1.67–1.51, 1.47–1.38 (all m, 
6H, H-2′, H-3′, H-4′); 13C NMR (100 MHz, CDCl3, β-anomer) δ 190.9 (COPhen), 171.0, 170.6, 
170.0, 169.9 (4 × COCH3), 167.6 (C-1), 136.8, 133.8 (2 × C-Ar), 134.3, 129.1, 128.6, 128.2, 
128.0 (CH-Ar), 99.6 (C-2), 70.9 (C-6), 68.2 (C-7), 67.3 (C-4), 67.0 (CH2Phen), 66.7 (CH2Ph), 
64.6 (C-1′), 64.4 (C-5), 62.8 (C-8), 41.1 (C-5′), 32.8 (C-3), 29.7, 29.2, 23.2 (C-2′, C-3′, C-4′), 
20.92–20.85 (4 × COCH3); HRMS (ESI-TOF) m/z [M + H]
+ calcd for C37H46NO15 744.2862; 
found 744.2878; m/z [M + Na]+ calcd for C37H45NNaO15 766.2681; found 766.2699; m/z [2M + 
Na]+ calcd for C74H90N2NaO30 1509.5471; found 1509.5505.  
 
4′-Methoxyphenacyl [2-(1-Nonyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-
ulopyranosid]onate (22). Thioglycoside 2 (50 mg, 84 µmol, 1.0 equiv, β/α 7:1) and 1-nonanol 
(10, 22 µL, 130 µmol, 1.5 equiv) were reacted according to the general procedure for 
glycosylation with thioglycoside donors and gave 22 (37 mg, 65%, β/α 5.3:1.0) as a yellow oil. 
[α]D
20 = +48 (c 0.4, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.92–7.88 (m, 2H, CH-
Ar), 6.99–6.95 (m, 2H, CH-Ar), 5.47 (d, J = 15.8 Hz, 1H, CHHPhen), 5.42–5.39 (m, 1H, H-5), 
5.36 (d, J = 15.8 Hz, 1H, CHHPhen), 5.35 (ddd, J3ax,4 = 13.0 Hz, J3eq,4 = 4.6 Hz, J4,5 = 3.1 Hz, 
1H, H-4), 5.22 (ddd, J7,8a = 9.6 Hz, J7,8b = 4.3 Hz, J6,7 = 3.1 Hz, 1H, H-7), 4.41–4.35 (m, 3H, H-
8a, H-8b, H-6), 3.89 (s, 3H, OCH3), 3.81 (dt, J = 9.0, 6.5 Hz, 1H, H-1a′), 3.48 (dt, J = 9.0, 6.8 
Hz, 1H, H-1b′), 2.54 (ddd, J3eq,3ax = 12.5 Hz, J3eq,4 = 4.8 Hz, J3,5 = 0.8 Hz, 1H, H-3eq), 2.17 (t, 
J3eq,3ax ≈ J3ax,4 ≈ 12.7 Hz, 1H, H-3ax), 2.12, 2.02, 2.00 (all s, 12H, 4 × COCH3), 1.64–1.56 (m, 
2H, H-2′), 1.36–1.24 (m, 12H, H-3′, H-4′, H-5′, H-6′, H-7′, H-8′), 0.88 (t, J = 6.8 Hz, 3H, H-9′); 
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13C NMR (100 MHz, CDCl3, β-anomer) δ 189.1 (COPhen), 170.9, 170.6, 170.0, 169.9 (4 × 
COCH3), 167.7 (C-1, 
3
JC1,H3ax = 5.2 Hz), 164.4 (C-Ar), 130.2 (2 × CH-Ar), 126.9 (C-Ar), 114.3 
(2 × CH-Ar), 99.6 (C-2), 70.9 (C-6), 68.3 (C-7), 67.4 (C-4), 66.7 (CH2Phen), 65.0 (C-1′), 64.5 
(C-5), 62.8 (C-8), 55.7 (OCH3), 32.8 (C-3), 32.0, 29.8, 29.6, 29.5, 29.4, 26.0, 22.8 (C-2′, C-3′, C-
4′, C-5′, C-6′, C-7′, C-8′), 20.91, 20.86 (2C), 20.83 (4 × COCH3), 14.2 (C-9′); HRMS (ESI-TOF) 
m/z [M + H]+ calcd for C34H49O14 681.3117; found 681.3091; m/z [M + Na]
+ calcd for 
C34H48NaO14 703.2936; found 703.2913; m/z [2M + Na]
+ calcd for C68H96NaO28 1385.5980; 
found 1386.5926. 
 
Benzyl [2-(1-Nonyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-ulopyranosid]onate 
(23). Thioglycoside 3 (50 mg, 93 µmol, 1.0 equiv, β/α 7:1) and 1-nonanol (10, 24 µL, 140 µmol, 
1.5 equiv) were reacted according to the general procedure for glycosylation with thioglycoside 
donors and gave 23 (37 mg, 87%, β/α 3.5:1.0) as a yellow oil. [α]D
20 = +42 (c 5.2, CHCl3); 
1H 
NMR (400 MHz, CDCl3, β-anomer) δ 7.39–7.34 (m, 5H, CH-Ar), 5.28–5.16 (m, 4H, H-5, H-7, 
CH2Ph), 4.87 (ddd, J3ax,4 = 13.2 Hz, J3eq,4 = 4.6 Hz, J4,5 = 3.0 Hz, 1H, H-4), 4.35–4.33 (m, 2H, H-
8a, H-8b), 4.20 (dd, J6,7 = 9.6 Hz, J5,6 = 1.4 Hz, 1H, H-6), 3.70 (dt, J = 9.1, 6.6 Hz, 1H, CHH), 
3.17 (dt, J = 9.1, 6.8 Hz, 1H, CHH), 2.40 (dd, J3eq,3ax = 12.5 Hz, J3eq,4 = 4.5 Hz, 1H, H-3eq), 2.10 
(t, J3eq,3ax ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.10, 2.09, 2.00, 1.98 (all s, 12H, 4 × COCH3), 1.51–
1.44 (m, 2H, CH2), 1.33–1.19 (m, 12H, 6 × CH2), 0.88 (t, J = 6.8 Hz, 3H, CH3); 
13C NMR (100 
MHz, CDCl3, β-anomer) δ 170.9, 170.7, 170.0, 169.9 (4 × COCH3), 168.0 (C-1, 
3
JC1,H3ax = 6.4 
Hz), 135.1 (C-Ar), 128.9–128.5 (CH-Ar), 99.6 (C-2), 70.8 (C-6), 68.2 (C-7), 67.8 (CH2Ph), 67.5 
(C-4), 65.0 (CH2), 64.3 (C-5), 62.7 (C-8), 32.7 (C-3), 32.0, 29.68, 29.65, 29.5, 29.4, 26.0, 22.8 (7 
× CH2), 20.92, 20.86, 20.84, 20.82 (4 × COCH3), 14.3 (CH3); HRMS (ESI-TOF) m/z [M + Na]
+ 
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calcd for C32H46NaO12 645.2881; found 645.2887; m/z [2M + Na]
+ calcd for C64H92NaO24 
1267.5871: found 1267.5890. 
 
4′-Methoxyphenacyl (2-Cyclohexyl 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-
ulopyranosid)onate (24). Thioglycoside 2 (50 mg, 84 µmol, 1.0 equiv, β/α 7:1) and cyclohexanol 
(11, 13 µL, 130 µmol, 1.5 equiv) were reacted according to the general procedure for 
glycosylation with thioglycoside donors and gave 24 (40 mg, 76%, β/α 4.0:1.0) as a yellow oil. 
[α]D
20 = +43 (c 4.3, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.92–7.88 (m, 2H, CH-
Ar), 6.99–6.94 (m, 2H, CH-Ar), 5.47 (d, J = 15.9 Hz, 1H, CHHPhen), 5.41–5.40 (m, 1H, H-5), 
5.36 (ddd, J3ax,4 = 12.9 Hz, J3eq,4 = 4.7 Hz, J4,5 = 3.2 Hz, 1H, H-4), 5.33 (d, J = 15.8 Hz, 1H, 
CHHPhen), 5.19 (ddd, J6,7 = 9.6 Hz, J7,8b = 4.9 Hz, J7,8a = 2.3 Hz, 1H, H-7), 4.40 (dd, J8a,8b = 12.1 
Hz, J7,8a = 2.3 Hz, 1H, H-8a), 4.38 (dd, J6,7 = 9.6 Hz, J5,6 = 1.4 Hz, 1H, H-6), 4.33 (dd, J8a,8b = 
12.3 Hz, J7,8b = 4.9 Hz, 1H, H-8b), 3.89–3.83 (m, 1H, CHCy), 3.88 (s, 3H, OCH3), 2.53 (ddd, 
J3ax,3eq = 12.4 Hz, J3eq,4 = 4.7 Hz, J3eq,5 = 0.7 Hz, 1H, H-3eq), 2.16 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.4 Hz, 
1H, H-3ax), 2.11, 2.02, 1.999, 1.994 (all s, 12H, 4 × COCH3), 1.95–1.14 (m, 10H, 5 × CH2Cy);
 
13C NMR (100 MHz, CDCl3, β-anomer) δ 189.2 (COPhen), 170.8, 170.6, 170.1, 169.8 (4 × 
COCH3), 168.2 (C-1, 
3
JC1,H3ax = 5.2 Hz), 164.4 (C-Ar), 130.2 (2 × CH-Ar), 126.9 (C-Ar), 114.3 
(2 × CH-Ar), 99.8 (C-2), 74.5 (CHCy), 70.8 (C-6), 68.4 (C-7), 67.4 (C-4), 66.7 (CH2Phen), 64.5 
(C-5), 62.8 (C-8), 55.6 (OCH3), 34.8, 33.6 (2 × CH2Cy), 33.1 (C-3), 25.5, 24.5, 24.4 (3 × CH2Cy), 
20.90, 20.85 (2C), 20.82 (4 × COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for 
C31H40NaO14 659.2310; found 659.2315; m/z [2M + Na]
+
 calcd for C62H80NaO28 1295.4728; 
found 1295.4732. 
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Benzyl (2-Cyclohexyl 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-ulopyranosid)onate 
(25). Thioglycoside 3 (50 mg, 93 µmol, 1.0 equiv, β/α 7:1) and cyclohexanol (11, 15 µL, 140 
µmol, 1.5 equiv) were reacted according to the general procedure for glycosylation with 
thioglycoside donors and gave 25 (43 mg, 80%, β/α 2.2:1.0) as a yellow oil. [α]D
20 = +69 (c 0.69, 
CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.41–7.33 (m, 5H, CH-Ar), 5.27–5.25 (m, 1H, 
H-5), 5.26 (d, J = 12.0 Hz, 1H, CHHPh), 5.18 (d, J = 12.0 Hz, 1H, CHHPh), 5.16 (ddd, J6,7 = 9.5 
Hz, J7,8b = 4.6 Hz, J7,8a = 2.3 Hz, 1H, H-7), 4.85 (ddd, J3ax,4 = 13.2 Hz, J3eq,4 = 4.6 Hz, J4,5 = 3.0 
Hz, 1H, H-4), 4.37 (dd, J8a,8b = 12.3 Hz, J7,8a = 2.4 Hz, 1H, H-8a), 4.31 (dd, J8a,8b = 12.3 Hz, J7,8b 
= 4.7 Hz, 1H, H-8b), 4.15 (dd, J6,7 = 9.5 Hz, J5,6 = 1.4 Hz, 1H, H-6), 3.66–3.58 (m, 1H, CHCy), 
2.40 (ddd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.6 Hz, J3eq,5 = 0.8 Hz, 1H, H-3eq), 2.09 (t, J3ax,3eq ≈ J3ax,4 ≈ 
12.3 Hz, 1H, H-3ax), 2.09, 2.06, 2.00, 1.97 (all s, 12H, 4 × COCH3), 1.94–1.00 (m, 10H, 5 × 
CH2Cy);
 13C NMR (100 MHz, CDCl3, β-anomer) δ 170.7, 170.6, 169.94, 169.91 (4 × COCH3), 
168.3 (C-1, 3JC1,H3ax = 6.2 Hz), 134.9, (C-Ar), 128.7–128.3 (CH-Ar), 99.8 (C-2), 74.6 (CHCy), 
70.7 (C-6), 68.3 (C-7), 67.7 (CH2Ph), 67.2 (C-4), 64.2 (C-5), 62.6 (C-8), 34.8 (CH2Cy), 33.3 
(CH2Cy), 33.0 (C-3), 25.4, 24.4, 24.3 (3 × CH2Cy), 20.88, 20.82, 20.79, 20.77 (4 × COCH3); 
HRMS (ESI-TOF) m/z [M + Na]+ calcd for C29H38NaO12 601.2255; found 601.2246; m/z [2M + 
Na]+ calcd for C58H76NaO24 1179.4619; found 1179.4595.  
 
4′-Methoxyphenacyl [2-(2′-Adamantyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-
ulopyranosid]onate (26). Thioglycoside 2 (50 mg, 84 µmol, 1.0 equiv, β/α 7:1) and 2-
adamantanol (12, 19 mg, 130 µmol, 1.5 equiv) were reacted according to the general procedure 
for glycosylation with thioglycoside donors and gave 26 (34 mg, 58%, β/α 4.3:1.0) as a colorless 
oil. [α]D
20 = +7 (c 2.7, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.93–7.88 (m, 2H, CH-
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Ar), 6.99–6.94 (m, 2H, CH-Ar), 5.46 (d, J = 15.9 Hz, 1H, CHHPhen), 5.43–5.35 (m, 2H, H-4, H-
5), 5.33 (d, J = 15.9 Hz, 1H, CHHPhen), 5.17 (ddd, J6,7 = 9.5 Hz, J7,8b = 4.8 Hz, J7,8a = 2.2 Hz, 
1H, H-7), 4.39–4.34 (m, 2H, H-8a, H-6), 4.29 (dd, J8a,8b = 12.2 Hz, J7,8b = 5.0 Hz, 1H, H-8b), 
4.08–4.04 (m, 1H, CH-Ad), 3.89 (s, 3H, OCH3), 2.55 (ddd, J3ax,3eq = 12.0 Hz, J3eq,4 = 4.7 Hz, 
J3eq,5 = 0.9 Hz, 1H, H-3eq), 2.20 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.0 Hz, 1H, H-3ax), 2.16–2.06 (m, 2H, 
CH2-Ad), 2.12, 2.02, 2.00 (all s, 12H, 4 × COCH3), 2.06–2.01 (m, 1H, CH-Ad), 1.85–1.68 (m, 
9H, 3 × CH2-Ad, 3 × CH-Ad), 1.55–1.45 (m, 2H, CH2-Ad);
 13C NMR (100 MHz, CDCl3, β-
anomer) δ 189.3 (COPhen), 170.8, 170.6, 170.1, 169.8 (4 × COCH3), 168.2 (C-1, 
3
JC1,H3ax = 5.2 
Hz), 164.3 (C-Ar), 130.2 (2 × CH-Ar), 127.0 (C-Ar), 114.3 (2 × CH-Ar), 99.8 (C-2), 78.2 (CH-
Ad), 70.7 (C-6), 68.4 (C-7), 67.5 (C-4), 66.6 (CH2Phen), 64.5 (C-5), 62.8 (C-8), 55.7 (OCH3), 
37.7, 37.0, 36.8 (3 × CH2-Ad), 34.4, 33.5 (2 × CH-Ad), 33.2 (C-3), 31.69, 31.67 (2 × CH2-Ad), 
27.4, 27.1 (2 × CH-Ad), 20.92, 20.88 (2C), 20.85 (4 × COCH3); HRMS (ESI-TOF) m/z [M + 
Na]+ calcd for C35H44NaO14 711.2623; found 711.2604; m/z [2M + Na]
+ calcd for C70H88NaO28 
1399.5354; found 1399.5309. 
 
Benzyl [2-(2′-Adamantyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-
ulopyranosid]onate (27). Thioglycoside 3 (40 mg, 74 µmol, 1.0 equiv, β/α 7:1) and 2-
adamantanol (12, 16 mg, 110 µmol, 1.5 equiv) were reacted according to the general procedure 
for glycosylation with thioglycoside donors and gave 27 (35 mg, 74%, β/α 2.4:1.0) as a yellow 
oil. [α]D
20 = +54 (c 3.3, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.40-7.33 (m, 5H, CH-
Ar), 5.27–5.25 (m, 1H, H-5), 5.24 (d, J = 12.1 Hz, 1H, CHHPh), 5.16 (d, J = 12.2 Hz, 1H, 
CHHPh), 5.14 (ddd, J6,7 = 9.5 Hz, J7,8b = 4.7 Hz, J7,8a = 2.3 Hz, 1H, H-7), 4.87 (ddd, J3ax,4 = 13.2 
Hz, J3eq,4 = 4.6 Hz, J4,5 = 3.0 Hz, 1H, H-4), 4.34 (dd, J8a,8b = 12.2 Hz, J7,8a = 2.2 Hz, 1H, H-8a), 
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4.27 (dd, J8a,8b = 12.2 Hz, J7,8b = 4.8 Hz, 1H, H-8b), 4.13 (dd, J6,7 = 9.5 Hz, J5,6 = 1.4 Hz, 1H, H-
6), 3.86–3.82 (m, 1H, CH-Ad), 2.43 (dd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.6 Hz, 1H, H-3eq), 2.13 (t, 
J3ax,3eq ≈ J3ax,4 ≈ 12.9 Hz, 1H, H-3ax), 2.10, 2.08, 2.00, 1.98 (all s, 12H, 4 × COCH3), 2.11–1.96 
(m, 2H, CH2-Ad), 1.98–1.94 (m, 1H, CH-Ad), 1.79–1.68 (m, 3H, 2 × CH-Ad, CHHAd), 1.67–
1.58 (m, 4H, 2 × CH2-Ad), 1.51–1.33 (m, 4H, CH2-Ad, CH-Ad, CHH-Ad); 
13C NMR (100 MHz, 
CDCl3, β-anomer) δ 170.8, 170.7, 170.05, 169.98 (4 × COCH3), 168.4 (C-1,
 3
JC1,H3ax = 6.3 Hz), 
135.1 (C-Ar), 128.8–128.7 (CH-Ar), 99.8 (C-2), 78.2 (CH-Ad), 70.7 (C-6), 68.4 (C-7), 67.6 
(CH2Ph), 67.4 (C-4), 64.3 (C-5), 62.7 (C-8), 37.6, 36.9, 36.7 (3 × CH2-Ad), 34.3, 33.3 (2 × CH-
Ad), 33.1 (C-3), 31.7, 31.6 (2 × CH2-Ad), 27.4, 27.0 (2 × CH-Ad), 20.93, 20.89, 20.86, 20.85 (4 
× COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for C33H42NaO12 653.2568; found 653.2557; 
m/z [M + K]+ calcd for C33H42KO12 669.2308; found 669.2295; m/z [2M + Na]
+ calcd for 
C66H84NaO24 1283.5245; found 1283.5208. 
 
4′-Methoxyphenacyl [2-(1′-Adamantyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-
ulopyranosid]onate (28). Thioglycoside 2 (50 mg, 84 µmol, 1.0 equiv, β/α 7:1) and 1-
adamantanol (13, 19 mg, 130 µmol, 1.5 equiv) were reacted according to the general procedure 
for glycosylation with thioglycoside donors and gave 28 (23 mg, 40%, β/α 1.6:1.0) as a colorless 
oil. [α]D
20 = +34 (c 1.9, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.94–7.89 (m, 2H, 
CH-Ar), 7.00–6.94 (m, 2H, CH-Ar), 5.49 (d, J = 15.8 Hz, 1H, CHHPhen), 5.40–5.37 (m, 1H, H-
5), 5.33–5.18 (m, 3H, CHHPhen, H-4, H-7), 4.57 (dd, J6,7 = 9.6 Hz, J5,6 = 1.4 Hz, 1H, H-6), 4.48 
(dd, J8a,8b = 12.2 Hz, J7,8a = 2.2 Hz, 1H, H-8a), 4.32 (dd, J8a,8b = 12.2 Hz, J7,8b = 5.2 Hz, 1H, H-
8b), 3.89 (s, 3H, OCH3), 2.51 (ddd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.7 Hz, J3eq,5 = 0.8 Hz, 1H, H-3eq), 
2.21 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.15–2.10 (m, 3H, 3 × CH-Ad), 2.11, 2.026, 2.015, 
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1.99 (all s, 12H, 4 × COCH3), 1.96–1.90 (m, 6H, 3 × CH2-Ad), 1.66–1.58 (m, 6H, 3 × CH2-Ad); 
1H NMR (400 MHz, CDCl3, α-anomer) δ 7.94–7.89 (m, 2H, CH-Ar), 7.00–6.94 (m, 2H, CH-Ar), 
5.53 (d, J = 15.8 Hz, 1H, CHHPhen), 5.42–5.36 (m, 2H, H-5, H-4), 5.33–5.18 (m, 2H, CHHPhen, 
H-7), 4.69 (dd, J8a,8b = 12.3 Hz, J7,8a = 2.7 Hz, 1H, H-8a), 4.39 (dd, J6,7 = 9.4 Hz, J5,6 = 1.5 Hz, 
1H, H-6), 4.15 (dd, J8a,8b = 12.3 Hz, J7,8b = 3.8 Hz, 1H, H-8b), 3.89 (s, 3H, OCH3), 2.32–2.23 (m, 
2H, H-3eq, H-3ax), 2.15–2.10 (m, 3H, 3 × CH-Ad), 2.08, 2.07, 1.99, 1.98 (all s, 12H, 4 × 
COCH3), 1.96–1.90 (m, 6H, 3 × CH2-Ad), 1.66–1.58 (m, 6H, 3 × CH2-Ad);
 13C NMR (100 MHz, 
CDCl3, β-anomer) δ 189.5 (COPhen), 170.8, 170.7, 170.3, 170.1 (4 × COCH3), 169.9 (C-1, 
3
JC1,H3ax = overlapping), 164.3 (C-Ar), 130.3 (2 × CH-Ar), 127.0 (C-Ar), 114.2 (2 × CH-Ar), 98.9 
(C-2), 79.2 (C-Ad), 71.3 (C-6), 68.5 (C-7), 67.2 (C-4), 66.6 (CH2Phen), 64.6 (C-5), 63.2 (C-8), 
55.7 (OCH3), 43.6 (2C), 42.9 (3 × CH2-Ad), 36.3 (2C), 36.1 (3 × CH2-Ad), 35.5 (C-3), 31.22 
(2C), 31.17 (3 × CH-Ad), 21.0–20.8 (4 × COCH3); 
13C NMR (100 MHz, CDCl3, α-anomer) δ 
189.8 (COPhen), 170.7, 170.6, 170.2, 169.8 (4 × COCH3), 169.5 (C-1,
 3
JC1,H3ax < 1.0 Hz), 164.3 
(C-Ar), 130.3 (2 × CH-Ar), 127.3 (C-Ar), 114.3 (2 × CH-Ar), 97.9 (C-2); 78.2 (C-Ad), 68.9 (C-
6), 68.6 (C-7), 66.8 (C-4), 66.4 (CH2Phen), 65.0 (C-5), 61.9 (C-8), 55.7 (OCH3), 43.6 (2C), 42.9 
(3 × CH2-Ad), 36.3 (2C), 36.1 (3 × CH2Phen), 35.2 (C-3), 31.23 (2C), 31.17 (3 × CH-Ad), 21.0–
20.8 (4 × COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for C35H44NaO14 711.2623; found 
711.2604; m/z [2M + Na]+ calcd for C70H88NaO28 1399.5354; found 1399.5310. 
 
Benzyl [2-(1′-Adamantyl) 4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-
ulopyranosid]onate (29). Thioglycoside 3 (50 mg, 93 µmol, 1.0 equiv, β/α 7:1) and 1-
adamantanol (13, 21 mg, 140 µmol, 1.5 equiv) were reacted according to the general procedure 
for glycosylation with thioglycoside donors and gave 29 (30 mg, 51%, β/α 1.0:1.6) as a yellow 
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20 = +43 (c 3.4, CHCl3); 
1H NMR (400 MHz, CDCl3, β-anomer) δ 7.44–7.32 (m, 5H, 
CH-Ar), 5.28–5.15 (m, 4H, H-5, H-7, CH2Ph), 4.77 (ddd, J3ax,4 = 13.4 Hz, J3eq,4 = 4.5 Hz, J4,5 = 
2.9 Hz, 1H, H-4), 4.50 (dd, J6,7 = 9.6 Hz, J5,6 = 1.5 Hz, 1H, H-6), 4.46 (dd, J8a,8b = 12.3 Hz, J7,8a = 
2.1 Hz, 1H, H-8a), 4.30 (dd, J8a,8b = 12.3 Hz, J7,8b = 5.2 Hz, 1H, H-8b), 2.31 (ddd, J3ax,3eq = 12.6 
Hz, J3eq,4 = 4.5 Hz, J3eq,5 = 0.8 Hz, 1H, H-3eq), 2.12 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.6 Hz, 1H, H-3ax), 
2.10, 2.09, 2.01, 1.96 (all s, 12H, 4 × COCH3), 2.05–1.97 (m, 3H, 3 × CH-Ad), 1.81–1.75 (m, 
6H, 3 × CH2-Ad), 1.57–1.42 (m, 6H, 3 × CH2-Ad); 
1H NMR (400 MHz, CDCl3, α-anomer) δ 
7.44–7.32 (m, 5H, CH-Ar), 5.39–5.31 (m, 2H, H-5, H-4), 5.25–5.15 (m, 3H, CH2Ph, H-7), 4.68 
(dd, J8a,8b = 12.3 Hz, J7,8a = 2.7 Hz, 1H, H-8a), 4.34 (dd, J6,7 = 9.5 Hz, J5,6 = 1.5 Hz, 1H, H-6), 
4.14 (dd, J8a,8b = 12.3 Hz, J7,8b = 3.8 Hz, 1H, H-8b), 2.19 (ddd, J3ax,3eq = 12.4 Hz, J3eq,4 = 4.7 Hz, 
J3eq,5 = 1.0 Hz, 1H, H-3eq), 2.06, 2.05, 1.98, 1.96 (all s, 12H, 4 × COCH3), 2.05–1.97 (m, 3H, 3 × 
CH-Ad), 1.92 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.4 Hz, 1H, H-3ax), 1.81–1.75 (m, 6H, 3 × CH2-Ad), 1.57–
1.42 (m, 6H, 3 × CH2-Ad);
 13C NMR (100 MHz, CDCl3, β-anomer) δ 170.8, 170.7, 170.1, 169.9 
(4 × COCH3), 169.8 (C-1, 
3
JC1,H3ax = overlapping), 134.9 (C-Ar), 129.0–128.8 (5 × CH-Ar), 98.7 
(C-2), 79.0 (C-Ad), 71.3 (C-6), 68.4 (C-7), 67.7 (CH2Ph), 66.9 (C-4), 64.4 (C-5), 63.2 (C-8), 
43.5, 42.8 (2C, 3 × CH2-Ad), 36.2, 36.0 (2C, 3 × CH2-Ad), 35.3 (C-3), 31.1, 31.0 (2C, 3 × CH-
Ad), 20.9–20.8 (4 × COCH3); 
13C NMR (100 MHz, CDCl3, α-anomer) δ 170.59, 170.55, 170.51, 
170.1 (4 × COCH3), 169.4 (C-1, 
3
JC1,H3ax < 1.0 Hz), 134.8 (C-Ar), 129.0–128.8 (5 × CH-Ar), 97.6 
(C-2), 78.1 (C-Ad), 68.8 (C-6), 68.6 (C-7), 67.6 (CH2Ph), 66.8 (C-4), 65.0 (C-5), 61.9 (C-8), 
43.5, 42.8 (2C, 3 × CH2-Ad), 36.2, 36.0 (2C, 3 × CH2-Ad), 35.0 (C-3), 31.1, 31.0 (2C, 3 × CH-
Ad), 20.9–20.8 (4 × COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for 
C33H42NaO12 653.2568; found 653.2561; m/z [2M + Na]
+ calcd for C66H84NaO24 1283.5245; 
found 1283.5226. 
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(2→6)-(Methyl 2,3-di-O-benzyl-α-D-glucopyranoside) (30). Thioglycoside 2 (35 mg, 59 µmol, 
1.0 equiv, β/α 7:1) and methyl 2,3-di-O-benzyl-α-D-glucopyranoside (14, 30 mg, 80 µmol, 1.4 
equiv) were reacted according to the general procedure for glycosylation with thioglycoside 
donors and gave 30 (36 mg, 61%, β/α 5.0:1.0) as a yellow oil. [α]D
20 = +26 (c 1.7, CHCl3); 
1H 
NMR (400 MHz, CDCl3, β-anomer) δ 7.92–7.85 (m, 2H, CH-Ar), 7.43–7.26 (m, 10H, CH-Ar), 
7.00–6.95 (m, 2H, CH-Ar), 5.44 (d, J = 15.8 Hz, 1H, CHHPhen), 5.37–5.35 (m, 1H, H-5), 5.36 
(d, J = 15.8 Hz, 1H, CHHPhen), 5.25 (ddd, J3ax,4 = 13.0 Hz, J3eq,4 = 4.6 Hz, J4,5 = 2.9 Hz, 1H, H-
4), 5.20 (ddd, J6,7 = 9.4 Hz, J7,8b = 5.1 Hz, J7,8a = 2.1 Hz, 1H, H-7), 4.97 (d, J = 11.1 Hz, 1H, 
CHHPh), 4.87 (d, J = 11.1 Hz, 1H, CHHPh), 4.79 (d, J = 12.1 Hz, 1H, CHHPh), 4.67 (d, J1,2 = 
3.7 Hz, 1H, H-1Glc), 4.66 (d, J = 12.1 Hz, 1H, CHHPh), 4.41 (dd, J8a,8b = 12.5 Hz, J7,8a = 2.3 Hz, 
1H, H-8a), 4.37–4.29 (m, 2H, H-8b, H-6), 4.06 (dd, J6a,6b = 11.0 Hz, J5,6a = 2.1 Hz, 1H, H-6aGlc), 
3.89 (s, 3H, OCH3Phen), 3.87–3.80 (m, 2H, H-6bGlc, H-3Glc), 3.79–3.64 (m, 2H, H-5Glc, H-
4Glc), 3.53 (dd, J2,3 = 9.6 Hz, J1,2 = 3.5 Hz, 1H, H-2Glc), 3.42 (s, 3H, OCH3Glc), 2.50 (dd, 
J3ax,3eq = 12.6 Hz, J3eq,4 = 4.8 Hz, 1H, H-3eq), 2.22 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.6 Hz, 1H, H-3ax), 2.08, 
2.02, 2.00, 1.99 (all s, 12H, 4 × COCH3);
 13C NMR (100 MHz, CDCl3, β-anomer) δ 189.6 
(COPhen), 171.1, 170.6, 170.0, 169.9 (4 × COCH3), 167.4 (C-1, 
3
JC1,H3ax = 5.6 Hz), 164.5 (C-Ar), 
139.1, 138.4 (2 × C-Ar), 130.3–127.7 (CH-Ar), 126.7 (C-Ar), 114.3 (CH-Ar), 99.8 (C-2), 98.4 
(C-1Glc), 81.9 (C-3Glc), 79.6 (C-2Glc), 75.8, 73.3 (2 × CH2Ph), 71.1 (C-6), 70.4 (C-5Glc), 70.2 
(C-4Glc), 68.2 (C-7), 67.3 (C-4), 66.8 (CH2Phen), 64.3 (C-5), 63.7 (C-6Glc), 62.9 (C-8), 55.7 
(OCH3Phen), 55.3 (OCH3Glc), 32.4 (C-3), 20.9 (2C), 20.81, 20.76 (4 × COCH3); HRMS (ESI-
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TOF) m/z [M + Na]+ calcd for C46H54NaO19 933.3152; found 933.3122; m/z [2M + Na]
+ calcd for 
C92H108NaO38 1843.6411; found 1843.6353. 
 
Benzyl [(4,5,7,8-Tetra-O-acetyl-3-deoxy-α,β-D-manno-oct-2-ulopyranosyl)onate]-(2→6)-(Methyl 
2,3-di-O-benzyl-α-D-glucopyranoside) (31). Thioglycoside 3 (35 mg, 65 µmol, 1.0 equiv, β/α 
7:1) and methyl 2,3-di-O-benzyl-α-D-glucopyranoside (14, 33 mg, 88 µmol, 1.4 equiv) were 
reacted according to the general procedure for glycosylation with thioglycoside donors and gave 
31 (48 mg, 78%, β/α 3.7:1.0) as a yellow oil. [α]D
20 = +33 (c 3.6, CHCl3); 
1H NMR (400 MHz, 
CDCl3, β-anomer) δ 7.40–7.28 (m, 15H, CH-Ar), 5.26–5.24 (m, 1H, H-5), 5.21–5.19 (m, 2H, 
CH2Ph), 5.15 (ddd, J6,7 = 9.3 Hz, J7,8b = 4.7 Hz, J7,8a = 2.3 Hz, 1H, H-7), 4.97 (d, J = 11.2 Hz, 1H, 
CHHPh), 4.88 (ddd, J3ax,4 = 13.1 Hz, J3eq,4 = 4.6 Hz, J4,5 = 2.9 Hz, 1H, H-4), 4.78 (d, J = 12.0 Hz, 
1H, CHHPh), 4.77 (d, J = 11.2 Hz, 1H, CHHPh), 4.65 (d, J  = 12.2 Hz, 1H, CHHPh), 4.61 (d, J1,2 
= 3.6 Hz, 1H, H-1Glc), 4.34 (dd, J8a,8b = 12.5 Hz, J7,8a = 2.4 Hz, 1H, H-8a), 4.29 (dd, J8a,8b = 12.4 
Hz, J7,8b = 4.8 Hz, 1H, H-8b), 4.13 (dd, J6,7 = 9.5 Hz, J5,6 = 1.3 Hz, 1H, H-6), 3.99 (dd, J6a,6b = 
11.0 Hz, J5,6a = 2.0 Hz, 1H, H-6aGlc), 3.78 (t, J2,3 ≈ J3,4 ≈ 9.2 Hz, 1H, H-3Glc), 3.72–3.65 (m, 
1H, H-5Glc), 3.59 (dd, J6a,6b = 11.0 Hz, J5,6b = 5.2 Hz, 1H, H-6bGlc), 3.53–3.44 (m, 2H, H-4Glc, 
H-2Glc), 3.38 (s, 3H, OCH3), 2.40 (dd, J3ax,3eq = 12.5 Hz, J3eq,4 = 4.6 Hz, 1H, H-3eq), 2.15 (t, 
J3ax,3eq ≈ J3ax,4 ≈ 12.5 Hz, 1H, H-3ax), 2.064, 2.062, 2.00, 1.98 (all s, 12H, 4 × COCH3);
 13C NMR 
(100 MHz, CDCl3, β-anomer) δ 171.1, 170.5, 169.90, 169.88 (4 × COCH3), 167.6 (C-1, 
3
JC1,H3ax 
= 6.2 Hz), 139.0, 138.2, 134.9 (3 × C-Ar), 128.9–127.8 (15 × CH-Ar), 99.8 (C-2), 98.2 (C-1Glc), 
81.7 (C-3Glc), 79.7 (C-2Glc), 75.6, 73.3 (2 × CH2Ph), 71.0 (C-6), 70.3, 70.2 (C-5Glc, C-4Glc), 
68.1 (C-7), 67.9 (CH2Ph), 67.1 (C-4), 64.08 (C-6Glc), 64.06 (C-5), 62.7 (C-8), 55.2 (OCH3), 32.2 
(C-3), 20.9, 20.82, 20.79, 20.7 (4 × COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ calcd for 
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C44H52NaO17 875.3097; found 875.3117; m/z [2M + Na]
+ calcd for C88H104NaO34 1727.6301; 
found 1727.6336. 
 
2-(1-Nonyl) (4,5,7,8-Tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulopyranosid)onic Acid (32). Kdo 
glycoside 22 (25 mg, 37 µmol, 1.0 equiv) was dissolved in 90% AcOH(aq) (1.1 mL) and the 
solution was heated to 35 °C. Freshly activated zinc powder (170 mg) was added in portions 
during 2 h. The mixture was filtered over Celite, rinsed with a 90% AcOH(aq) solution (5 mL) 
and a solution of EtOH/EtOAc (4 × 10 mL, 1:1 v/v). The solvents were concentrated under 
reduced pressure to afford a residue, which was purified by silica gel flash chromatography 
(DCM/MeOH 1:0 to 8:2) to give carboxylic acid 32 (17 mg, 89%) as a white amorphous powder. 
[α]D
20 = +48 (c 1.8, MeOH); 1H NMR (400 MHz, MeOD) δ 5.22 (br s, 1H, H-5), 5.17 (br t, J = 
7.7 Hz, 1H, H-7), 5.00 (dt, J3ax,4 = 12.6 Hz, J3eq,4 = 3.6 Hz, 1H, H-4), 4.51 (d, J8a,8b = 12.0 Hz, 
1H, H-8a), 4.39 (d, J = 9.5 Hz, 1H, H-6), 4.27 (dd, J8a,8b = 12.0 Hz, J7,8b = 6.7 Hz, 1H, H-8b), 
3.75 (dd, J = 15.6, 6.7 Hz, 1H, H-1a′), 3.49 (dd, J = 15.2, 6.7 Hz, 1H, H-1b′), 2.39 (dd, J3eq,3ax = 
11.8 Hz, J3eq,4 = 4.0 Hz, 1H, H-3eq), 1.98 (t, J3eq,3ax ≈ J3ax,4 ≈ 11.8 Hz, 1H, H-3ax), 2.07, 2.03, 
1.98, 1.93 (all s, 12H, 4 × COCH3), 1.60–1.52 (m, 2H, H-2ab′), 1.39–1.23 (m, 12H, H-3ab′, H-
4ab′, H-5ab′, H-6ab′, H-7ab′, H-8ab′), 0.90 (t, J = 6.8 Hz, 3H, H-9′); 13C NMR (100 MHz, 
MeOD) δ 172.54, 172.45, 171.7, 171.6 (4 × COCH3), 102.3 (C-2), 72.0 (C-6), 70.0 (C-7), 69.7 
(C-4), 66.1 (C-5), 65.4 (C-1′), 64.7 (C-8), 33.9 (C-3), 33.0, 31.0, 30.7, 30.5, 30.4, 27.2, 23.7 (C-
2′, C-3′, C-4′, C-5′, C-6′, C-7′, C-8′), 20.7 (4 × COCH3), 14.4 (C-9′); HRMS (ESI-TOF) m/z [M 
+ Na]+ calcd for C25H40NaO12 555.2412; found 555.2423; m/z [2M + Na]
+ calcd for C50H80NaO24 
1087.4932; found 1087.4953. 
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deoxy-α,β-D-manno-oct-2-ulopyranosid]onic Acid (33). Kdo glycoside 15 (25 mg, 32 µmol, 1.0 
equiv) was dissolved in 90% AcOH(aq) (1.0 mL) and the solution was heated to 35 °C. Freshly 
activated zinc powder (170 mg) was added in portions over 2 h. The mixture was filtered over 
Celite, rinsed with a 90% AcOH(aq) solution (5 mL) and a solution of EtOH/EtOAc (4 × 10 mL, 
1:1 v/v). The solvents were concentrated under reduced pressure to afford a residue, which was 
purified by silica gel flash chromatography (DCM/MeOH 1:0 to 8:2) to give carboxylic acid 33 
(17 mg, 85%) as a white amorphous powder. [α]D
20 = +35 (c 1.1, CHCl3); 
1H NMR (400 MHz, 
CDCl3) δ 7.38–7.30 (m, 5H, CH-Ar), 5.29 (br s, 1H, H-5), 5.19 (dt, J6,7 = 9.6 Hz, J7,8a ≈ J7,8b ≈ 
3.1 Hz, 1H, H-7), 5.16–5.00 (m, 4H, CH2Ph, H-4, NHCbz), 4.40–4.32 (m, 1H, H-8a), 4.26 (d, J6,7 
= 9.6 Hz, 1H, H-6), 3.80–3.73 (m, 1H, H-1a′), 3.65 (t, J7,8a ≈ J7,8b ≈ 6.6 Hz, 1H, H-8b), 3.59–3.49 
(m, 1H, H-1b′), 3.24–3.07 (m, 2H, H-5ab′), 2.41 (dd, J3ax,3eq = 12.3 Hz, J3eq,4 = 4.3 Hz, 1H, H-
3eq), 2.06 (t, J3ax,3eq ≈ J3ax,4 ≈ 12.3 Hz, 1H, H-3ax), 2.10, 2.07, 2.01, 1.98 (all s, 12H, 4 × 
COCH3), 1.67–1.35 (m, 6H, H-2ab′, H-3ab′, H-4ab′);
 13C NMR (100 MHz, CDCl3) δ 171.2, 
170.7, 170.2, 170.0 (4 × COCH3), 136.5 (C-Ar), 128.6–128.3 (CH-Ar), 99.7 (C-2), 70.8 (C-6), 
66.2 (C-7), 67.6 (C-4), 67.1 (CH2Ph), 64.3 (C-5), 63.7 (C-1′), 62.9 (C-8), 41.2 (C-5′), 32.3 (C-3), 
29.9, 29.3, 23.0 (C-2′, C-3′, C-4′), 20.93–20.88 (4 × COCH3); HRMS (ESI-TOF) m/z [M + Na]
+ 
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